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Sp1-regulated expression of p11 contributes to
motor neuron degeneration by membrane insertion
of TASK1
Victoria García-Morales 1,2,5, Guillermo Rodríguez-Bey 1,5, Laura Gómez-Pérez 1,5,
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Disruption in membrane excitability contributes to malfunction and differential vulnerability
of specific neuronal subpopulations in a number of neurological diseases. The adaptor protein
p11, and background potassium channel TASK1, have overlapping distributions in the CNS.
Here, we report that the transcription factor Sp1 controls p11 expression, which impacts on
excitability by hampering functional expression of TASK1. In the SOD1-G93A mouse model of
ALS, Sp1-p11-TASK1 dysregulation contributes to increased excitability and vulnerability of
motor neurons. Interference with either Sp1 or p11 is neuroprotective, delaying neuron loss
and prolonging lifespan in this model. Nitrosative stress, a potential factor in human neu-
rodegeneration, stimulated Sp1 expression and human p11 promoter activity, at least in part,
through a Sp1-binding site. Disruption of Sp1 or p11 also has neuroprotective effects in a
traumatic model of motor neuron degeneration. Together our work suggests the Sp1-p11-
TASK1 pathway is a potential target for treatment of degeneration of motor neurons.
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Despite their different clinical manifestations, neurode-generative diseases share a multitude of common under-lying mechanisms. Of special relevance is intrinsic
membrane excitability (IME), determinant of neuronal respon-
siveness to incoming stimuli, which can condition specific neu-
ronal subpopulations to become differentially vulnerable in
neurodegenerative disorders1–4.
Both passive and active membrane properties are involved in
establishing neuronal IME. Passive properties, such as resting
membrane potential (Vm) and membrane resistance, are deter-
mined by the density of background ion channels opened at rest,
whereas active electrical signaling mainly relies on the activity of
voltage-gated and ligand-gated ion channels. IME alterations
interact with other pathogenic mechanisms, such as nitrosative
stress (RNS) and excitotoxicity, that contribute to neuronal
degeneration in many human neuropathologies1–6. For instance,
RNS, a major factor mediating excitotoxic neurodegeneration6–9,
enhances IME by inhibiting background potassium (K+) cur-
rents10, thus depolarizing Vm and increasing membrane resis-
tance. On the other hand, neuronal excitotoxicity arising from
disruption of Ca2+ homeostasis by overstimulation of glutamate
receptors (GluRs)7,11 might be amplified by an increased IME.
Depolarization of Vm exacerbates Ca2+ influx into the neuron by
promoting voltage-sensitive Ca2+ channels (VSCCs) opening and
by relieving N-methyl-D-aspartate receptors from the magnesium
blockage7,12,13. Ca2+ overload can in turn trigger RNS, closing a
vicious cycle with many still-unknown partners and leading to
neuronal degeneration and cell death.
The adaptor protein p11 (S100A10) could be a firm candidate
to fine-tune neuronal IME by regulating plasma membrane
insertion of TASK1 (TWIK-related acid-sensitive K+
subunit 1)14, a member of the KCNK family of two-pore-domain
K+ channels. This family primarily determines passive membrane
properties in mammalian cells, which confers it potential ther-
apeutic impact15,16. Expression patterns of p1117 and TASK118
predict their overlapping in many neuronal subpopulations vul-
nerable to certain neuropathological conditions. Particularly,
somatic motor neurons (MNs), which express high levels of p11
and TASK1, are vulnerable to amyotrophic lateral sclerosis (ALS);
a fatal neurodegenerative disease coursing with hyper-excitability
as one of the earliest manifestations in sporadic and familial ALS
patients3,4. Notably, enhanced IME, excitotoxicity, and RNS are
common hallmarks in MN degeneration models with differing
etiology, i.e. ALS1–6 and traumatic injury of a motor nerve6,19.
Therefore, we hypothesized that p11 and TASK1 are pivotal
partners in a common mechanism determining vulnerability to
neurodegeneration.
Our findings support that dysregulation of the ubiquitous
transcription factor Sp1, p11, and TASK1 contributes to MN
degeneration by impacting on MN IME and vulnerability.
Results
p11 determines MN IME by TASK1. Co-immunoprecipitation
studies supported a physical interaction between p11 and TASK1
in the nervous system (Fig. 1a). Subsequently, we examined by
whole-cell patch-clamp the impact of p11–TASK1 on MNs IME
(Fig. 1b). The strong reduction in mRNAp11, resulting from the
application of a small interfering RNA against mRNAp11 (siR-
NAp11), lowered IME of hypoglossal MNs (HMNs) from brain-
stem slices of rat pups (postnatal day 7; P7) (Fig. 1b–e). Whether
siRNAp11-related IME alterations were mediated by a regulatory
effect on TASK channel function was addressed by modifying
extracellular pH to characterize TASK-dependent changes in Vm
and input resistance (RN)10. Alkalination of extracellular medium
(pH 8.2) from a physiological pH (7.2) opens TASK channels,
enhancing K+ efflux, which leads to Vm hyperpolarization, and
reduction of RN (Fig. 1f). On the contrary, an acidic solution (pH
6.2) retains K+ into the cell by closing TASK channels, which
causes Vm depolarization and RN increase (Fig. 1f). Therefore,
the impact of pH on MN IME increases in parallel to the number
of functional TASK channels at the plasma membrane. Suggestive
of an increase in surface expression of TASK channels, siRNAp11
strengthened pH impact on HMNs IME (Fig. 1g). In contrast,
dexamethasone, a corticosteroid that stimulates p11 promoter
activity, upregulated p11 at the hypoglossal nucleus (HN),
increased IME, and reduced pH influence on HMNs IME (Sup-
plementary Fig. 1).
To evaluate whether p11 stablishes IME through TASK1,
further experiments were performed in primary cultures of
embryonic spinal cord MNs (SMNs). In our experimental
conditions, IME of wild-type SMNs (SMNswt) changed over
time in culture (Fig. 1h). Thus, whereas Vm and RN remained
steady throughout the first 3–4 days-in vitro (DIV), IME of
SMNswt progressively declined over the 4–6 DIV interval, and
subsequently remained stable up to 8 DIV, the last time point
tested (Fig. 1h). These outcomes are consistent with a progressive
increase in surface expression of functional background K+
channels at the 4–6 DIV interval. Therefore, next experiments
were carried out in SMNwt at 3–4 DIV (Fig. 1i), a time window
over which functional expression of TASK is still low.
Remarkably, p11 knockdown increased TASK1-like immuno-
fluorescence in the neurites of SMNswt (Fig. 1i–k, Supplementary
Fig. 2). Since siRNAp11 did not upregulate TASK1 protein
(Fig. 1i), our results support that p11 regulates cell distribution
rather than whole levels of TASK1 expression. Conclusively, while
decline in p11 did not affect SMNs isolated from task1−/−
embryos (SMNstask1−/−), it lowered IME and increased TASK-
dependent changes in SMNswt and SMNstask3−/− (lacking in
TASK3, also highly expressed in MNs) (Fig. 1l, m). It was
noteworthy that SMNswt either untreated or treated with a non-
targeting siRNA (cRNA) were almost unresponsive to pH
variations despite TASK1 expression (Fig. 1i,m, Supplementary
Fig. 2), suggesting a low surface expression of pH-modulated
channels at 3–4 DIV. Altogether, these findings support that
physical interaction between p11 and TASK1 prevents functional
expression of the channel at the plasma membrane, which in turn
controls MN IME.
p11–TASK1 defines MN vulnerability to an excitotoxic insult.
GluR overstimulation induces intracellular Ca2+ deregulation
and Ca2+ homeostasis disruption that finally leads to cell
death7,11. To evoke this harmfulness mechanism, SMNs were
exposed to a toxic dose of glutamate (Fig. 2a, Supplementary
Fig. 3a, b). Ca2+ imaging showed a glutamate-induced early
rapid rise in intracellular Ca2+ concentration ([Ca2+]i) in
SMNswt which peaked and then progressively dropped to a
lower plateau (Fig. 2a, Supplementary Fig. 3a, b). This plateau
was transient in 90.4 ± 4.6% of cases (n= 164 SMNswt). Fol-
lowing this initial plateau, SMNswt generally experienced “Ca2+
deregulation”, a delayed and continued increase in [Ca2+]i that
reached a mostly sustained and irreversible plateau (Fig. 2a,
Supplementary Fig. 3a, b), indicative of impending neuronal
death20,21. To characterize Ca2+ dynamics in SMNs, resting
[Ca2+]i, peak [Ca2+]i of the early rapid response to glutamate
and time of Ca2+ deregulation were measured (Supplementary
Fig. 3b). siRNAp11 strongly attenuated glutamate-evoked Ca2+
dynamics (Fig. 2a, Supplementary Fig. 3c–e), although did not
alter the fraction of SMNs that underwent Ca2+ deregulation
with regard to genotype (Supplementary Fig. 3f). Kaplan–Meier
cumulative probability curves causally associated siRNAp11
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Fig. 1 p11 controls MN IME through TASK1, but not TASK3 subunits. a Co-immunoprecipitation (IP) of p11 and TASK1 in protein fractions of homogenized
brain from an adult mouse. An anti-sheep IgG was a control. Elution 1 (E1) and 2 (E2) are displayed. b Left, experimental model for whole-cell patch clamp
recordings from HMNs in brainstem slices. Inset, a micropipette (white arrow) close to the MN pool is showed. Right, voltage responses (top) to step
hyperpolarizing currents (bottom) of two HMNs recorded from P7 rats receiving indicated oligonucleotides at P5. Dots, time points used to measure the
peak voltage response to construct the I–V plot (see the “Methods” section). c, d Microinjection of siRNAp11 (2 μg/2 μl) into the fourth ventricle of P5 rats
reduced mRNAp11 levels in the brainstem at P7. e Vm and RN of HMNs recorded under pH 7.2. f Schematic summarizing effects of extracellular pH on MN
IME and TASK-mediated K+ currents. Int intracellular, Ext extracellular. g Changes in Vm and RN induced by variation of extracellular pH from 8.2 to 6.2
(TASK-dependent changes). h Time-course of Vm and RN obtained from recorded SMNswt at the indicated days-in vitro (DIV) after seeding. i Effect of
siRNAp11 or cRNA (2 μM) on p11 and TASK1 in SMNswt by western blot. j Confocal images showing that siRNAp11 (2 μM) leads to a drastic reduction in p11
immunolabelling (red) together with an increase in TASK1 expression (green) in neuritic processes of SMNswt, as compared to cRNA (2 μM). Scale bar,
5 μm. k Box-plots of the mean (top) and integrated (bottom) intensity (in arbitrary units, a.u.) of TASK1 immunolabelling in neurites after treatments. l, m
As in e, g, respectively, but from SMNs of the indicated genotypes under the specified treatments. Number of independent samples in each group is in
parentheses. Error bars, SEM. *p < 0.05, **p < 0.01, ***p < 0.001; ns, not significant; by Student t-test d, e, g, k, l, one-way analysis of variance (ANOVA)
with post hoc Holm–Sidak method i, m (Vm) or ANOVA on Ranks with post hoc Dunn’s method m (RN). Source data are provided as a Source Data file
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treatment with a noticeable delay in the time of Ca2+ dereg-
ulation (i.e., likely prolonging the cell lifespan) in SMNswt and
SMNstask3−/− but, remarkably, not in SMNstask1−/− (Fig. 2b).
siRNAp11-mediated attenuation of the intracellular Ca2+
response to glutamate involved reduction of Ca2+ entry
through at least GluRs and VSCCs (Supplementary Note 1,
Supplementary Fig. 3f–k).
Since MN IME is mainly determined by TASK channels
(TASK1/3 heterodimers, as well as TASK1/1 and TASK3/3
homodimers)18,22, we first investigated their impact on SMNs
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survival. These experiments were performed in SMNs at 4–5 DIV,
when an increase in surface expression of TASK channels is
expected (see Fig. 1h). Drugs used for this purpose and their
effects on TASK-mediated currents are summarized in Fig. 2c. A
broad-spectrum TASK blocker, bupivacaine, reduced SMNswt
survival like glutamate (Fig. 2d, Supplementary Fig. 4a, b);
however, bupivacaine potentiated glutamate harmfulness
(Fig. 2d). Interestingly, the anesthetic isoflurane, a TASK1/3
and TASK3/3 opener, and a TASK1/1 blocker, compromised
survival per se and potentiated glutamate toxicity in SMNstask3−/−
but blocked and reduced glutamate toxicity in SMNswt and
SMNstask1−/−, respectively (Fig. 2e). Furthermore, the selective
TASK1 blocker anandamide (AEA, 10 μM), increased IME,
reduced survival, and potentiated glutamate toxicity in SMNswt
and SMNstask3−/− but, conclusively, not in SMNstask1−/−
(Fig. 2f–h, Supplementary Fig. 4c). However, AEA at a lower
concentration (3 μM) did not modify either IME or SMNswt
survival (Fig. 2g, Supplementary Fig. 4c). The detrimental effects of
AEA on SMNswt survival were insensitive to AM281, a
cannabinoid receptor-1 antagonist (Supplementary Fig. 4d). Alto-
gether, TASK channels, and among them TASK1 subunits,
determine MN IME and survival, as well as MN vulnerability to
an excitotoxic insult. Therefore, promoting functional expression
of TASK1 by reducing p11 is a reasonable strategy to protect MNs
against excitotoxicity. Accordingly, siRNAp11-induced p11 down-
regulation protected SMNswt and SMNstask3−/− but, again, not
SMNstask1−/−, from glutamate (Fig. 2i, j, Supplementary Fig. 5a).
Overall, p11 downregulation lowers MN IME by promoting
TASK1 insertion at plasma membrane, then attenuates Ca2+ influx
through GluRs and VSCCs, and subsequently reduces vulnerability
to excitotoxic degeneration (Fig. 2k).
p11 knockdown is neuroprotective in the SOD1-G93A model.
The outstanding impact of p11 on MN IME, Ca2+ signaling, and
vulnerability to an excitotoxic insult suggests a leading role of p11 in
neurodegenerative processes and highlights disruption of p11
function as a promising neuroprotective strategy. The superoxide
dismutase 1 (SOD1)-G93A transgenic mouse model of familial ALS
is the most widely used model in basic and preclinical studies of
ALS. In this model, disease progression courses from hind to
forelimbs. Hence, we focused our studies on MN pools located at
the ventral horn of the lumbar spinal cord. In wild-type adult mice,
MNs were the cell type in the ventral horn with highest levels of
mRNAp11 and p11 (Fig. 3a, b). In contrast, astrocytes within and
surrounding MN clusters only rarely and weakly displayed p11
immunoreactivity (Fig. 3c). At the pre-symptomatic stage (1-
month-old), mRNAp11 and mRNAtask1 were already upregulated
in the spinal cord of transgenic mice (Fig. 3d). Although
mRNAp11 and p11 upregulation persisted throughout the symp-
tomatic phase (4-month-old), both mRNAtask1 and TASK1
declined (Fig. 3d). At the early-symptomatic stage (3-month-old)
that precedes MN loss, p11 was upregulated in lumbar SOD1-
G93A MNs as compared to those from non-transgenic (Non-Tg)
littermates (Fig. 3e). At this stage, p11-positive astrocytes were
abundant within the characteristic astroglial reaction observed in
the ventral horn of SOD1-G93A mice (Fig. 3f).
Experiments performed on SMNs provide evidence for a MN
autonomous role of p11 upregulation in the ALS model. SMNs
from SOD1-G93A embryos (SMNsG93A) recapitulated
p11–TASK1 dysregulation observed in the spinal cord of
symptomatic mice (Supplementary Fig. 5b). In agreement with
a reduced functional expression of TASK1 channels, SMNsG93A
exhibited a more excitable state than that of Non-Tg SMNs
(SMNsNon-Tg) (Supplementary Fig. 5c). Ca2+ imaging shed light
on a gain-in-function of p11 for managing Ca2+ dynamics in
SMNsG93A (Supplementary Fig. 5d–h). Under cRNA, SMNsG93A
showed higher resting [Ca2+]i and peak [Ca2+]i of the early rapid
response to glutamate, but shorter time of Ca2+ deregulation than
SMNsNon-Tg (Supplementary Fig. 5d–h). Remarkably, neuropro-
tective effects of siRNAp11 on the disturbance of Ca2+ dynamics
were greater in SMNsG93A (resting: −39.9 ± 8.8%; peak: −45.0 ±
4.1%; Δ time of Ca2+ deregulation: +347.8 ± 15.4 s) than in
SMNsNon-Tg (resting: −33.4 ± 6.4%; peak: −34.5 ± 8.6%; Δ time
of Ca2+ deregulation:+139.7 ± 10.1 s) (Supplementary Fig. 5d–g).
Kaplan–Meier analysis of Ca2+ deregulation reported that, under
cRNA-treatment, the probability function of SMNsG93A was
displaced to the left (i.e., likely shortening the cell lifespan)
relative to SMNsNon-Tg (p < 0.001). Noticeably, no differences
(p= 0.130) were found between the two groups of siRNAp11-
treated SMNs (Supplementary Fig. 5h). The probability curves for
both of these groups were displaced to the right (i.e., likely
prolonging the cell lifespan; p < 0.001), compared to those from
their respective cRNA-treated pools (Supplementary Fig. 5h).
Finally, SMNsG93A were more vulnerable to glutamate than
SMNsNon-Tg and, as expected, siRNAp11 robustly increased survival
of SMNsG93A exposed to glutamate (Supplementary Fig. 5i).
Hence, potential neuroprotective effects of siRNAp11 was assessed
in the ALS model. We firstly tested the efficacy of a weekly injection
of cRNA or siRNAp11 into the 4th ventricle to affect lumbar MNs,
beginning at the pre-symptomatic stage (2-month-old), once the
skull was developed enough to implant the injection system
(Fig. 3g). By using this procedure, we observed that siRNAp11
consistently reduced mRNAp11 and p11 protein in the lumbar
spinal cord after 8 weeks of treatment (Supplementary Fig. 6a, b).
Quantitative analysis of p11-immunolabelling in lumbar MNs
revealed that the decline in labeling intensity was already evident
Fig. 2 p11 controls Ca2+ signaling and vulnerability to an excitotoxic stimulus through TASK1, but not TASK3 subunits. a Dimensional displays (left) and
time course of [Ca2+]i alterations (right) obtained from SMNs treated with cRNA or siRNAp11 (2 μM) from 1 DIV. Red horizontal lines indicate the
glutamate (Glu, 150 μM) exposure interval. b Log-Rank test, Kaplan–Meier analysis reported that siRNAp11 (dotted lines) delayed Ca2+ deregulation in
SMNswt and SMNstask3−/− (p < 0.001), but not SMNstask1−/− (p= 0.761) relative to that in the cRNA condition. n= 36–49 SMNs. Ca2+ imaging studies
were performed at 3–4 DIV. c Schematic summarizing effects of listed drugs on TASK-mediated currents. d Effects of bupivacaine (Bupiv; 40 μM, 60min)
and Glu (150 μM, 30min), added alone or in combination, on SMNswt survival. e Effects of isoflurane (Iso; 0.8 mM each 10min for 70min) and Glu, added
alone or in combination, on SMNswt, SMNstask1−/−, and SMNstask3−/− survival. f Influence of AEA (10 μM) on Vm of a SMNwt at 4–5 DIV. g Changes in
Vm (left) and RN (right) of SMNswt, SMNstask1−/−, and SMNstask3−/− induced by AEA at the indicated concentrations. Number of SMNs in each group is
in parentheses. h Effects of AEA (10 μM, 60min) added alone or in combination with Glu on the survival of the indicated groups of SMNs. i Dose-
dependent effects of siRNAp11 on the survival of SMNswt exposed to Glu (30min, 150 μM). cRNA (5 μM) was taken as an additional control. Mean number
of SMNswt in the untreated condition was taken as 100%. j Mean effects of siRNAp11 (2 μM) on survival of SMNstask1−/− and SMNstask3−/−. No NTFs,
culture medium not supplemented with neurotrophic factors. Schematics in d–f, h, i represent experimental protocols. Error bars, SEM. *p < 0.05, **p <
0.01, ***p < 0.001; ns, not significant; by Student's t-test g or one-way analysis of variance (ANOVA) with post hoc Holm–Sidak method d, e, h–j. d, e, h–j
n≥ 3 independent experiments. k Schematic diagram depicting a neuroprotective strategy by interfering with p11 function (with siRNAp11 in the example).
Source data are provided as a Source Data file
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2 weeks after beginning of siRNAp11-treatment (Supplementary
Fig. 6c). Thereafter, the number of SMI32-positive MNs in the
L3–L5 lumbar segment from 4-month-old mice was quantified.
Chronic administration of siRNAp11 in SOD1-G93A mice, which
reduced p11-immunoreactivity in the lumbar spinal cord (Fig. 3h),
attenuated MN loss and improved motor performance (rotarod,
footprint, runtime, and grip strength) as compared with cRNA-
treated animals (Fig. 3i, Supplementary Fig. 6d–h). Correspond-
ingly, siRNAp11 delayed symptoms onset, alleviated weight loss, and
prolonged survival (cRNA: 125.0 ± 1.8 days; siRNAp11: 135.3 ±
3.0 days, p < 0.001, Student's t-test) in SOD1-G93A mice (Fig. 3j–l).
Beneficial effects did not result from different levels of transgene
expression in both cohorts (Supplementary Fig. 6i).
p11 knockdown is neuroprotective in the nerve injury model.
In situ hybridization and immunohistochemistry studies clearly
showed that HMNs, but not astrocytes, express high levels of
p11 in the adult mouse (Fig. 4a, b). Bidirectional trophic
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communication between MNs and their target myocytes is
necessary to keep MNs alive. Therefore, resection of a segment of
the XIIth nerve, in which the possibility of nerve regeneration was
minimized, led to significant loss of neurons in the HN (Fig. 4c,
d). Neuronal loss was still undetectable one week post-lesion.
However, a significant drop in the number of neurons was
observed 2 weeks post-injury and, progressively declined up to
~40% from 4th to 8th week post-lesion (Fig. 4d). Remarkably,
p11 was upregulated in the HN preceding MN loss (Fig. 4e). p11
upregulation was evident as soon as one day after injury and rose
at 7th days post-lesion (Fig. 4e). p11 induction in the HN was
mainly associated with upregulation in HMNs. p11-positive
astrocytes were not observed in the injured side, even though the
characteristic astroglial reaction occurred in the injured side
(Fig. 4f, g). It was also interesting to note that, one week after
nerve resection, mRNAtask1 declined in the injured HN (Fig. 4e),
just as in the spinal cord of symptomatic SOD1-G93A mice.
To explore cell-specificity of p11 to MN loss, neuron-specific
lentiviral constructions (LVVs) (Fig. 4c), which direct the
expression of a small hairpin RNA against p11 (LVV-shRNAp11)
or against bacterial lacz (LVV-shRNAlacz), were used. LVV-
shRNAp11 reduced mRNAp11, enhanced TASK-dependent
changes, and protected SMNswt against glutamate (Supplemen-
tary Fig. 7). Furthermore, a single intramedullar microinjection of
LVV-shRNAp11, led to a drastic reduction of mRNAp11 and p11
in both HNs 24 days after viral administration (Fig. 4h).
Interestingly, LVV-shRNAp11 microinjection in the injured HN
reduced both p11 expression in injured, but not in intact HMNs,
and cell loss (Fig. 4i, j). Therefore, neuron-specific p11 knock-
down was neuroprotective for axotomized MNs.
The reached outcomes in both degenerative models highlight
p11 upregulation as a key event in an overall mechanism
contributing to MN degeneration in diverse motor pathologies
regardless of causal origin.
RNS upregulates p11 and inhibits TASK-like currents. In order
to obtain a more complete picture of this pathogenic mechanism, we
looked for a widespread pathological event upstream p11 upregu-
lation. In this context, large quantities of nitric oxide (NO) lead to
RNS, a potential factor in excitotoxic neurodegeneration6–9. Inter-
estingly, NO has been reported to upregulate p11 in human bron-
chial epithelial cells via protein kinase G (PKG)23. Finally, RNS
inhibits TASK-mediated currents in MNs throughout PKG10
(Fig. 5a). Here, RNS was simulated by long-term action (≥4 h) of
DETA/NO (1mM). At this concentration, this NONOate releases
pathological amounts of NO, as estimated in vivo6,7,24,25, over a 24-h
period. NO inhibited TASK-like currents in HMNs independently of
short-term mechanisms such as direct Gαq co-association26 and/or
Rho-kinase (ROCK)-mediated phosphorylation27, since a Gαq
inhibitor or short-term presence (15min) of a ROCK inhibitor did
not prevent/revert long-term effects of DETA/NO (Supplementary
Fig. 8a–c). However, the long-term mechanism involved RhoA-
ROCK signaling, but not dysregulation of TASK1 and TASK3
expression (Supplementary Fig. 8d–g).
As reported for smooth muscle cells28, NO, via PKG, increased
both, the amount of the phosphorylated form of the transcription
factor ATF-1 and RhoA in the HN of neonatal rats (Fig. 5b, c).
Conclusively, DETA/NO, via PKG-ROCK, upregulated mRNAp11
and p11, but not mRNAtask1 or mRNAtask3 (Fig. 5c–e). Further-
more, DETA/NO-evoked p11 upregulation and pH-responsiveness
reduction were fully blocked by retinoic acid, which post-
translationally reduces p11 levels (Supplementary Fig. 9a–c),
strengthening the notion that RNS inhibits TASK-like channels
in a p11-dependent way. Several additional findings support a
pathological NO-p11-TASK association in damaged MNs: (i) XIIth
nerve crushing at P3 induces neuronal NO synthase (nNOS)
expression in MNs6, and MN loss at P10, but not at P7 (Fig. 5f;
Supplementary Fig. 9d, e); (ii) RhoA and p11 upregulation in the
injured HN, together with hyper-excitability and reduction in
TASK-mediated currents of injured HMNs, precede neuron
loss (Fig. 5g–j); (iii) daily administration of the NOS inhibitor
L-NAME fully prevents RhoA and p11 upregulation, and
substantially preserves TASK-mediated currents in damaged
HMNs (Fig. 5f–j); (iv) intracerebroventricular microinjection of
siRNAp11 increases TASK-dependent changes in IME in axoto-
mized HMNs (Fig. 5f, j); and (v) treatment of brainstem slices (P7)
with retinoic acid down-regulates p11 in the injured side and
partially recovers pH-responsiveness of insulted HMNs (Supple-
mentary Fig. 9f–h).
Therefore, in axotomized MNs, RNS resulted in the recruit-
ment of the PKG–RhoA–ROCK pathway to upregulate p11, thus
reducing TASK-mediated currents underlying hyper-excitability
that precedes MN loss (Fig. 5k).
RNS stimulates the human p11 promoter via a Sp1-binding
site. To strengthen clinic and translational potential, we tested
RNS effects on luciferase activity coupled to the human p11
promoter (region −1436 to +89) in the transfected and differ-
entiated MN-like cell line NSC34 (dNSC34). In preliminary
experiments, DETA/NO induced mRNAp11 and p11 in dNSC34s
(Supplementary Fig. 10a), indicating their capability to cou-
ple p11 expression to NO. Only DETA/NO concentrations
(1–2mM), releasing pathological amounts of NO, increased luci-
ferase activity (Fig. 6a), in a time-dependent manner (Supple-
mentary Fig. 10b). We chose a 48-h treatment with DETA/NO 1
mM as the optimal condition for subsequent experiments. DETA/
NO stimulated luciferase activity through the NO target and PKG-
activator soluble guanylyl cyclase (sGC), PKG, and ROCK
Fig. 3 Neuroprotective effects of siRNAp11 in the SOD1-G93A mouse model of ALS. a In situ hybridization (ISH, from the Allen Brain Atlas) and
immunohistochemistry (ICH) showing the expression pattern of p11 in the lumbar spinal cord of adult wild-type mice. b, c Confocal images of lumbar spinal
cords immunolabeled for p11 and the MN marker SMI32 b or the astroglial marker GFAP c. d mRNA (left) and protein (right) levels of p11 and TASK1 in the
spinal cord of SOD1-G93A mice and their Non-Tg littermates, at the indicated stages (see schematic on top). e p11 immunofluorescence (left) and mean
intensity (arbitrary units, a.u.; right) of labeling in lumbar MNs of indicated mice and age. MNs were identified as in b. f Confocal images showing astroglial
reaction in the ventral horn of SOD1-G93A mice. Double immunolabeling reported p11-immunoreactive astrocytes in the boxed area. g Schematic of timing
for injection system implantation and cRNA/siRNAp11 administration. h p11 immunohistochemistry performed in lumbar spinal cord sections obtained from
indicated mice which received cRNA or siRNAp11 from P60. Insets, examples of two vacuolated MNs with different levels of p11 immunostaining. i Number
of SMI32-identified MNs in the L3–L5 spinal cord segments of 4-month-old mice with the indicated genotypes that received the stated treatments
beginning at P60. The box indicates the area of the ventral horn containing the MN pools that were quantified. Scale bars, b, c, e, 50 μm; a, c, 100 μm; h, i,
300 μm. j–l Cumulative probability curves of symptom onset j, survival l, and time course of mean body weight k for cRNA-treated and siRNAp11-treated
SOD1-G93A mice. Number of independent samples in each group is in parentheses. Statistic outputs are displayed in plots. Error bars, SEM. *p < 0.05, **p
< 0.01, ***p < 0.001; n.s., not significant; by Student t-test d, e, i or two-way ANOVA with post hoc Holm–Sidak method k. Log-Rank test, Kaplan–Meier
analysis was applied to j and l. Source data are provided as a Source Data file
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(Fig. 6b). Furthermore, serial 5′ promoter deletions isolated a
minimal NO-responsive element at the −96 to −70 segment
(Fig. 6c). Finally, site-directed mutagenesis identified a potential
binding site for Sp1 (GC-box) essential for NO-responsiveness
(Fig. 6d). Since, three additional Sp1 and a NO-responsive AP-1-
binding sites upstream −96 have been identified23,29, whether p11
promoter is regulated by other NO-responsive elements and/or by
still unrevealed factors remains to be investigated.
Electrophoretic mobility shift assays (EMSA) displayed two
well-defined complexes when the wild-type −96 to −70 sequence
was incubated with nuclear protein extracts from dNSC34s.
Both complexes were absent if the sequence comprised the
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NO-irresponsive mutation (Fig. 6e). Competitive inhibition, by
increasing the concentration of the canonical Sp1 sequence,
reduced complex formation in a dose-dependent manner (Fig. 6f).
In addition, incubation with antibodies against Sp1 or Sp3 either
alone or in combination clearly reduced the intensity of the
complex with lower electrophoretic mobility (Fig. 6g). Altogether,
these outcomes support a binding of Sp1, and probably Sp3, to
the NO-sensitive GC-box within the −96 to −70 segment of p11
promoter. Finally, DETA/NO at 1 mM, but not at 0.1 mM,
upregulated mRNASp1 and mRNAp11 in SMNswt via the PKG-
ROCK signaling (Fig. 6h, i), further supporting that DETA/NO
effects on promoter activity result in an increase in transcriptional
activity of the p11 gene in murine MNs.
Therefore, we hypothesize that RNS, established under
neurological conditions by pathological concentrations of NO,
recruits sGC–PKG–ROCK signaling and subsequently upregu-
lates the transcription factor Sp1, which stimulates p11 promoter
activity and promotes p11 expression (Fig. 6j).
Mit-A, a feasible neuroprotector that dysregulates p11–TASK1.
Based on the preceding framework, we tested the viability of
interference with Sp1 function as a neuroprotective strategy.
Transient transfection of a plasmid directing the expression of a
truncated form of Sp1, which acts as a dominant negative
(dnSp1), strongly reduced p11 in dNSC34s (Supplementary
Fig. 11a, b). Furthermore, a neuron-specific LVV directing the
expression of dnSp1 (LVV-dnSp1) reduced mRNAp11, strongly
promoted functional expression of TASK-like channels, and
almost fully blocked glutamate toxicity on SMNswt (Supplemen-
tary Fig. 11c–e). These data support that Sp1 controls constitutive
expression of p11 in dNSC34s and SMNswt. Nevertheless, given
the current limitations of LVVs for medical use, we tested a Sp1-
interfering drug with higher clinical potential. In this context,
Mit-A, a FDA-approved anticancer antibiotic that binds to GC-
rich sequences, is usually used to interfere with Sp1 binding to its
target sites.
Mit-A fully avoided NO-triggered stimulation of the minimal
NO-responsive element of the human p11 promoter (Supple-
mentary Fig. 12a). This antibiotic strongly reduced mRNAp11 and,
unexpectedly, increased mRNAtask1 levels in SMNswt, both of
which would be expected to result in additive functional effects
(Supplementary Fig. 12b). Thus, Mit-A drastically lowered IME
and promoted TASK-mediated changes in SMNswt and
SMNstask3−/−, but, conclusively, not in SMNstask1−/− (Supple-
mentary Fig. 12c–g). Mit-A also attenuated glutamate-evoked
Ca2+ homeostasis disruption in a TASK1-dependent manner
(Supplementary Fig. 12h–j). Kaplan–Meier analysis revealed that
Mit-A caused a strong delay in the time of Ca2+ deregulation (i.e.,
likely prolonging the cell lifespan) in SMNswt and SMNstask3−/−,
but again not in SMNstask1−/− (Supplementary Fig. 12k). Finally,
Mit-A protected SMNswt and SMNstask3−/− but, once again, not
SMNstask1−/−, against glutamate toxicity (Supplementary
Fig. 12l). These results strengthen the therapeutic interest of
Mit-A by reducing neuronal hyper-excitability and vulnerability
against excitotoxicity.
Mit-A is neuroprotective in the SOD1-G93A model. Both Sp1
upregulation in the spinal cord from symtomatic (4-month-old)
SOD1-G93A mice, and the increase of nuclear immunolabelling
for Sp1 in lumbar MNs preceding cell loss (3-month-old)
underpin a key role for Sp1 in the ALS model (Fig. 7a, b). Sp1 was
also upregulated in SMNsG93A (Supplementary Fig. 13a).
Accordingly, Mit-A lowered IME, promoted TASK-dependent
changes and strongly attenuated glutamate-triggered Ca2+ dis-
turbance in SMNsG93A (Supplementary Fig. 13b–g). The
Kaplan–Meier analysis of Ca2+ deregulation showed that Mit-A
displaced to the right the probability function of SMNsG93A
(Supplementary Fig. 13h), and lowered their vulnerability to
glutamate (Supplementary Fig. 13i).
Therefore, neuroprotective action of Mit-A is underpinned by
the additive action on p11 and TASK1 expression, which lowers
IME and delays glutamate-evoked Ca2+ deregulation, at least in
part, by promoting TASK1 expression at the plasma membrane
(Fig. 7c). Then, we tested preclinical efficacy of Mit-A in SOD1-
G93A mice. Initially, optimal dosage of Mit-A was determined in
wild-type mice. Chronic and daily administration of growing
doses of Mit-A in the drinking water for 3 weeks, reduced p11 and
increased TASK1 expression in the spinal cord (Supplementary
Fig. 14a, b). Given that p11 reduction after all tested doses was
similar, we primarily selected the lower one (30 μg kg−1 day−1) for
chronic treatment. This dose for 2 weeks reduced and increased,
respectively, p11 and TASK1-like subunits in lumbar MNs
(Supplementary Fig. 14c, d). Furthermore, daily administration
of Mit-A from P30 kept p11–TASK1 appropriately dysregulated in
the spinal cord and attenuated the loss of lumbar MNs in 4-
month-old SOD1-G93A mice (Fig. 7d, e). Mit-A delayed
symptoms onset, alleviated weight loss, prolonged survival, and
improved motor performance in SOD1-G93A mice (Fig. 7f–h;
Supplementary Fig. 14e–g). Antibiotic-induced neuroprotective
effects were substantiated by functional benefits at the muscle.
Myocytes denervation is a characteristic hallmark of ALS,
identified in needle electromyography by spontaneous discharges
of skeletal muscle fibers or fibrillations (Fig. 7i). Thus, the
frequency of fibrillations gradually increased in transgenic mice
from week 13 to week 16 of age but these were generally absent in
Non-Tg animals (Fig. 7j–m). Interestingly, the rate of fibrillations
Fig. 4 Cell-type specific p11 dysregulation is pivotal in a traumatic model of MN degeneration. a In situ hybridization (ISH, from the Allen Brain Atlas) and
immunohistochemistry (ICH) showing the expression pattern of p11 in the HN of adult wild-type mice. b Confocal images showing p11 in SMI32-labeled
HMNs (top) but not in GFAP-positive astrocytes (bottom). c Top, experimental design. Bottom, images illustrating neuronal-specificity of a lentivirus,
which direct the expression of eGFP. d Effect of resection of a 2-mm segment of the XIIth nerve and immediate proximal stump ligation on the number of
HMNs in adult mice. A neutral red-stained coronal section at the indicated post-injury time is shown on top. e Western blots (top) and plot (bottom, left)
showing p11 upregulation in the injured (Inj) relative to the intact (Int) HN. Empty circle, sham condition. Bottom, right, qRT-PCR analysis. f p11 upregulation
(top) and astroglial reaction (bottom) in the insulted HN after nerve injury. g Double immunohistochemistry showed p11 expression in SMI32-identified
HMNs but not in GFAP-positive astrocytes in the damaged side. h Effect of microinjection of indicated LVVs in the midline between both HNs c on protein
and mRNA levels for p11 in HNs. Neocortex was a control for systemic transduction. gapdh and α-tub were internal controls for qRT-PCR and western
blotting, respectively. i LVV-shRNAp11 microinjection, 3 days before nerve injury (see schematic in j), reduced p11 labeling in SMI32-identified HMNs
relative to LVV-shRNAlacz. Mean intensity (arbitrary units, au) of p11 labeling in injured/intact HMNs (top) or in the intact/non-injected side (bottom) after
indicated LVVs injection. j LVV-shRNAp11 reduced neuronal loss, as assessed by Nissl staining in the injured versus the intact HN. In d, e, i (top), j, data
values in the injured side are displayed relative to those obtained for the intact side. Scale bars, c (right), 20 μm; a–c (left), f, g, i, 100 μm; d, j, 500 μm.
Number of independent samples is in parentheses. Error bars, SEM. *p < 0.05, **p < 0.01, ***p < 0.001; n.s., not significant; by Mann–Whitney test d, e, h,
Student t-test i or one-way ANOVA with post hoc Holm–Sidak method j. Source data are provided as a Source Data file
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under Mit-A treatment was drastically decreased at all ages tested
(Fig. 7j–m).
Similar outcomes were observed when Mit-A treatment
(30 μg kg−1 day−1) began at 2 months of age in ALS mice
(Supplementary Fig. 15a–f). Although two additional drug
regimens (30 or 150 μg kg−1 day−1), beginning at P90, pro-
longed survival and improved rotarod performance of SOD1-
G93A mice (Supplementary Fig. 15c, d), the results were not
conclusive on the beneficial effects of these treatments in the
remaining parameters (Supplementary Fig. 15a, b, e, f). The
higher dose tested even worsened body weight, footprint, and
runtime outcomes over the time-course (Supplementary
Fig. 15b, e, f).
Finally, Mit-A (30 μg kg−1 day−1) and Riluzole (25mg kg−1
day−1), the most clinically used drug for ALS patients, resulted in
similar beneficial outputs in SOD1G93A mice when parallel
treatments began at 2 months of age (Supplementary Fig. 15g–m).
Mit-A is neuroprotective in the motor nerve injury model. One
week after resection of a 2-mm-segment of the XIIth nerve of
adult mice, Sp1 was increased in the HN of the injured side
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(Fig. 8a). Sp1-immunolabelling was enhanced in the injured side
at 7 days after injury (Fig. 8b, c), thus preceding HMNs loss (see
Fig. 4d). Interestingly, lesion-induced Sp1 upregulation was
avoided by 2 days treatment with the NOS inhibitor L-NAME
(Fig. 8d). Furthermore, chronic administration of the NOS
inhibitor or Fasudil (10 mg kg−1 day−1), an inhibitor of the
downstream NO-acting ROCK (see Fig. 6j), reduced the loss of
injured HMNs (Fig. 8e). All these pharmacological treatments
began at 5 days post-lesion, when de novo expression of nNOS in
injured MNs was evidenced30. These outcomes indicate that Sp1
upregulation, downstream de novo NO synthesis, is part of a
mechanism that precedes MN death after motor nerve injury.
Mit-A administration in the drinking water at two doses (30 or
300 μg kg−1 day−1) drastically reduced neuron loss observed
21 days after nerve resection (Fig. 8f). Neuroprotection was
confirmed in task3−/−, but was absent in task1−/− mice (Fig. 8f).
Intraperitoneal administration of the higher dose of Mit-A
(300 μg kg−1 day−1) showed slight but significant neuroprotective
effects (Fig. 8f). Therefore, Mit-A delays MN degeneration after
nerve injury, by a mechanism involving, at least, TASK1 subunits.
Therefore, Sp1 is also a feasible partner in an overall
mechanism contributing to MN degeneration and point to the
therapeutic interest of Mit-A for the treatment of diverse motor
pathologies regardless of causal origin.
Cell-specific Sp1–p11 knockdown protects SOD1-G93A MNs.
p11 upregulation occurs in astrocytes and MNs before MN loss
in SOD1-G93A mice (see Fig. 3e, f). Then, we studied a cell
autonomous role of Sp1–p11 in MN degeneration. In this
context, most used MN-specific conditional knockouts mice
target the subset of MNs that is mainly spared in the disease
(VAChT:Cre model)31–35, or other cells types besides MNs
(Hb9:Cre model)36–38, including spinal cord interneurons
involved in rhythm generation during locomotor activity.
Therefore, here we performed intraspinal microinjections of
neuron-specific LVV-dnSp1 or LVV-shRNAp11 (see Fig. 4c)
into the ventral horn of the lumbar segments in 2-month-old
SOD1-G93A mice (Fig. 9a). A careful inspection of the L1–L3
ventral horns from 4-month-old animals showed the presence
of the reporter protein GFP in p11-immunoreactive MNs, but
not in glial-like structures (Fig. 9b–e). Strikingly, p11-
immunolabelling was reduced in GFP-positive MNs after
LVV-dnSp1 or LVV-shRNAp11 injection (Fig. 9c–f). Further-
more, the frequency of vacuolated/degenerating MNs was
higher in LVV-shRNAlacz- compared to LVV-dnSp1/LVV-
shRNAp11-treated SOD1-G93A mice (Fig. 9g, h). Accordingly,
the number of apparently healthy MNs was higher in
mice receiving LVV-dnSp1 or LVV-shRNAp11 than in those
treated with LVV-shRNAlacz (Fig. 9g–i). Therefore, these
outcomes, together with those from SMNs, strongly support a
cell autonomous role of Sp1/p11 in MN degeneration.
However, whether p11 upregulation in glial cells also con-
tributes in some degree to disease progression merits further
investigation.
Discussion
Our study identify a mechanism that regulates neuronal IME,
Ca2+ signaling, and vulnerability to degeneration. The ubiquitous
transcription factor Sp1 controls the expression of p11, a reten-
tion factor at the endoplasmic reticulum for TASK114, which
regulates channel expression at the cell surface, thus fine-tuning
neuronal IME and Ca2+ influx via GluRs and VSCCs (Fig. 10a).
Interference with Sp1 function reduces p11 expression and
attenuates MN IME, Ca2+ dynamics, and vulnerability via
TASK1. These effects were similar to those revealed by disrupting
p11. Hence, we conclude that modulation of the Sp1–p11–TASK1
triad offers a promising strategy to minimize excitotoxic damage
occurring in a multitude of neuropathologies associated with
dysregulated membrane excitability and/or excitotoxic degen-
eration, including both acute and chronic neurodegenerative
diseases7,8.
Of pathological relevance, Sp1–p11–TASK1 dysregulation
occurs in two motor neurodegenerative models with very different
causal origins, which shared excitotoxicity and hyper-excitability
as pathophysiological hallmarks3,4,6. Sp1–p11–TASK1 strongly
impacts on IME of MNs. Interfering with either Sp1 or p11 lowers
MNs IME by promoting functional expression of TASK1, then
protecting MNs against excitotoxicity. However, whether hyper-
excitability is harmful or neuroprotective for MNs in ALS is a
current subject of debate. Intrinsic hyper-excitability of MNs has
been assumed to participates in the excitotoxic process39. In
contrast, hyper-excitability is proposed as a transitory state40,41
that even might be beneficial42,43 in ALS, and which might
underlie survival of S-type MNs in the ALS model42,43. Here, at
early-presymptomatic (P30) stage, p11 and TASK1 upregulation
could be part of a homeostatic and compensatory process to
neutralize deficits during early phases of disease43. Nevertheless,
persistent p11 upregulation and TASK1 down-expression occur-
ring at the symptomatic stage might potentiate excitotoxic pro-
cesses39 by strengthening, for example, the incoming synaptic
excitation to MNs that might result from inhibitory bouton loss
and excitatory synapse gain44. In this line, chronic interference
with Sp1 and/or p11 beginning at presymptomatic (P30 or P60) or
early-symptomatic (P90) stages resulted neuroprotective for
SOD1-G93A MNs and/or mice.
Fig. 5 RNS upregulates p11 and inhibits TASK channels in a traumatic model of MN degeneration. a Effects of nerve injury or persistent action of the NO-
PKG pathway on MN IME and TASK-mediated currents. b–e Expression of phosphorylated ATF-1 (pATF-1) and RhoA proteins b, indicated mRNAs c, d and
p11 e in HNs from neonatal brainstem slices incubated for 6 h in aCSF alone (control), or supplemented with either DETA/NO (1 mM), DETA/NO+PKG-i
(10 μM), DETA/NO+H1152 (20 μM), or DETA/NO+Y27632 (10 μM). In c, mRNA levels of DETA/NO versus control condition are presented. In b–e, n≥ 3
independent experiments. f Experimental model. Crushing was inflicted to the XIIth nerve of P3 rats. Pups were untreated, L-NAME-treated, or they
received a single intracerebroventricular microinjection of cRNA or siRNAp11. g Immunoblots for RhoA and p11 of HNs from P7 rats treated as shown. gapdh
and α-tub were the internal controls for qRT-PCR and western blotting, respectively. h Averaged I–V relationships of the TASK-mediated current for the
indicated treatments (see experimental design in f) (see Supplementary Fig. 9b). Data were well fitted (r > 0.9) with the Goldman–Hodgkin–Katz equation
(solid line). Current reversed close to −90mV, near the reversal potential predicted for K+ (EK). Goldman–Hodgkin–Katz fits for control and DETA/NO
(dashed lines), previously reported10, are shown for comparison. i Top, current-clamp recordings of the voltage responses to a series of depolarizing and
hyperpolarizing current pulses (0.5 s duration, 0.04 nA increments) from a control and a damaged HMN recorded 4 days after axonal injury. Bottom, time
courses illustrating alterations in current holding (Iholding) recorded in response to extracellular pH changes for two P7 HMNs held at −65mV. j Plots
represent TASK-dependent changes in Vm and RN for each listed treatment group. Number of independent samples is in parentheses. Error bars, SEM. *p <
0.05, **p < 0.01, ***p < 0.001; n.s., not significant; by Student's t-test c, g or one-way ANOVA with post hoc Holm–Sidak method b, d, e, j. k Schematic
diagram depicting the mechanism by which RNS impacts on MN IME. Source data are provided as a Source Data file
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Additional controversy comes from passive membrane
properties that lie behind hyper-excitability in SOD1-G93A
MNs. While embryonic (E17.5)45 and early-postnatal
(P6–P10)46 spinal MNs displayed RN increase or Vm depolar-
ization, respectively, no changes in Vm nor RN accompanied
hyper-excitability in HMNsG93A (P4–P10)47. Here, hyper-
excitability of SMNsG93A (E12.5), recorded at 4–5 DIV,
involved Vm depolarization and RN increase. Interestingly,
hyper-excitable SMNsG93A (E12–E15)48,49, recorded at 10–30
DIV, did not displayed Vm and RN alterations. This agrees with
an early transitory state in which these passive membrane
properties of SMNsG93A are affected. All these discrepancies
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might be due to different embryonic origin (spinal cord vs.
brainstem), developmental stage (embryonic vs. neonatal), and/
or experimental preparations.
Several findings support causality between RNS and
Sp1–p11–TASK1 dysregulation. First, Sp1 expression and its
DNA-binding activity increased in rat hippocampus exposed to
excitotoxic insults50,51. Second, nNOS induction preceded MN
death in ALS and after nerve injury6. Third, DETA/NO (0.1 mM)
did not alter human p11 promoter activity or Sp1–p11 expres-
sion. However, DETA/NO (1 mM), which releases pathological
concentrations of NO6,24,25, increases MN IME by inhibition of
TASK-like channels, upregulates Sp1–p11, and stimulates human
p11 promoter via at least a Sp1-binding GC-box. Consistently,
NO upregulated p11 in human epithelial cells23 and promoted
Sp1-binding activity52–54. Fourth, Sp1-interfering agent Mit-A
fully avoids RNS-triggered stimulation of the minimal NO-
responsive element of the human p11 promoter. Fifth, inhibition
of endogenous NO synthesis attenuates the Sp1–p11 upregulation
and the TASK-dependent increase of MN IME in the nerve injury
model. Therefore, Sp1–p11–TASK1 dysregulation downstream of
RNS seems a key event in a positive feedback loop leading to
excitotoxic degeneration (Fig. 10b).
Comparison of the timing of NOS-p11 upregulation after
injury30 and in the ALS model6, suggests that early p11 induction
was RNS-unrelated in the two models (Fig. 10b). Thus, early
slight p11 upregulation after nerve injury (1–3 days) and in the
ALS model (early-presymptomatic) precede NOS induction after
nerve injury (3–5 days)30 and in SOD1-G93A mice (late-pre-
symptomatic)6. Furthermore, given that NOS induction occurs in
MNs and glial cells in early-symptomatic SOD1-G93A mice
preceding MN loss6, whether p11 expression at this stage is
coupled to NO from MN and/or glia origin merits further
investigation (Fig. 10b). Sp1 ubiquity and broad co-expression of
p11 and TASK1 all along the CNS17,18, suggest the need for
further investigation on this triad to ascertain feasible biomarkers
for diverse psychiatric and neurological disorders. One of the
three, p11, has recently been proposed as a biomarker for mon-
itoring the severity of Parkinson’s disease55.
The Sp1-binding inhibitor Mit-A is neuroprotective in the ALS
mouse model. The oral lower dose we administered (30 μg kg−1
day−1) is in the lower range for its intravenous application in
humans56–58. We would expect that concentration of Mit-A that
might be reached within the organism after oral administration was
lower than that obtained with equivalent intravenous doses in
chemotherapy. In this line, characteristic side-effects after intrave-
nous Mit-A administration (bleeding, behavioral alterations, and
weight loss)56–58 were absent in treated mice. Strikingly, beneficial
outcomes of Mit-A treatment on SOD1-G93A mice were similar to
those achieved under treatment with Riluzole, the most used drug
for ALS patients in clinical settings. Currently, Mit-A is the subject
of clinical trials for several cancers (http://www.ClinicalTrials.gov;
Identifiers: NCT02859415, NCT01624090), thus supporting a
renewed interest in the clinical use of this kind of compounds. The
present results along with the emergence of Mit-A analogs with
higher activity and less toxicity59–61 encourage the use of these
drugs in clinical trials for neurodegenerative disorders60 such
as ALS.
In summary, RNS-triggered induction of Sp1–p11 decreases
background K+ currents and switches neuron to a more vul-
nerable configuration in neurodegenerative disorders. In contrast,
a reduction in Sp1–p11 places neurons in a more resistant state
against degeneration due to an increase in the functional
expression of TASK1. The broad expression of Sp1–p11–TASK1
throughout the organism suggests that interplay between these
proteins might not only be circumscribed to the CNS but may
also impact functioning of the immune, cardiovascular, respira-
tory, digestive, excretory, and reproductive systems, both in
health and in sickness62–64. Indeed, dysregulation of either Sp1,
p11, or TASK1 has been independently reported in multiple
pathological conditions, including inflammatory processes and
cancer, affecting different organs and tissues.
Methods
Animals. Neonatal (P3–P9) wistar rats of either sex, young (1–2-month-old) and
adult (>2-month-old) male mice, either CD1, SOD1-G93A (Jackson Laboratory, Bar
Harbor, ME, USA) and Non-Tg littermates; and, CD1, C57BL/6J, task1−/−, task3−/−,
and SOD1-G93A pregnant mice (12.5 days gestation). All these animals were pro-
vided by the local Animal Supply Services (SEPA, University of Cadiz). Animal care
and handling followed the guidelines of the European Union Council (2010/63/EU,
86/609/UE) on the use of laboratory animals. Experimental procedures were approved
by the local Animal Care and Ethics Committee (University of Cadiz, Cadiz, Spain)
and the Ministry of Agriculture, Fisheries and Rural Development (Junta de Anda-
lucía, Spain). task1−/− and task3−/− mice, a gift from Dr. Douglas A. Bayliss (Uni-
versity of Virginia, VA, USA), became stablished colonies and were bred in the local
Animal Supply Services. Animals were individually housed in cages with water and
food pellets available ad libitum, at 21 ± 1 °C, with a 12-h light/dark cycle. Neonatal
animals were housed with their mother. Efforts were made to minimize the number of
animals used and their suffering. All surgical processes were carried out under aseptic
conditions.
Electrophysiology. Whole-cell patch-clamp recordings were performed in HMNs
from coronal brainstem slices (P6–P9 rats) or cultured SMNs (4 DIV)10,65–67. In
summary, neonatal rats were decapitated under anesthesia by hypothermia
(10–15 min at 4 °C). Brainstems were rapidly removed and dissected in artificial
cerebrospinal fluid (aCSF) enriched with sucrose at 4 °C (in mM: 26 NaHCO3, 10
glucose, 3 KCl, 1.25 NaH2PO4, 2 MgCl2, and 218 sucrose), and bubbled with 95%
O2 and 5% CO2. Transverse slices (300–400 μm-thick), obtained using a vibroslicer
(NVSL; WPI), were transferred to normal oxygenated aCSF (in mM: 26 NaHCO3,
Fig. 6 RNS stimulates the human p11 promoter through a Sp1-binding site. a, b Luciferase activity (in arbitrary units, a.u.) coupled to the human p11
promoter from transfected dNSC34 incubated for 48 h either with the indicated DETA/NO concentrations a or with drugs modulating the NO/sGC/PKG-
ROCK signaling pathway b. c Luciferase activity displayed by the indicated serial 5′ promoter deletions in untreated (control) or DETA/NO-treated
transfected dNSC34s. NO-induced changes, in folds relative to the mean value for untreated (control) condition, are presented on the right plot. d Top,
sequence of the human p11 promoter from −96 to +7. A regulatory AP-2/Sp1-binding site is highlighted (blue). G/C to T site-directed mutations are also
shown (Mut 1–Mut 5). Middle, as in c for the −96 to +89 segment of the promoter including each of mutations. The −70 to +89 segment was used as a
NO-unresponsive control. As a negative control, mutation of the AP-2/Sp1-binding site downstream −7029 did not alter NO-responsiveness. Bottom, NO-
responsive GC-box element identified by site-directed mutagenesis. e–g EMSAs obtained by incubating 32P-labeled −96 to +89 wild-type or Mut 5 probes
with three independent nuclear protein extracts (1, 2, 3) from dNSC34s or in the absence of nuclear extracts (−) e. Competition assays by co-addition of
canonical sequences for Sp1 and AP-2 at the indicated concentrations f, or super-shift analysis with antibodies (2 μg μl−1) against Sp1 and/or Sp3 g. h Time
course of changes in mRNASp1 and mRNAp11 expression in SMNswt incubated with the stated drugs beginning at 6 DIV relative to that obtained from
untreated SMNswt at the respective time points. DETA/NO (0.1 mM) for 24 or 72-h did not affect mRNA levels. DETA (1 mM, 72 h) was a negative
control. n= 3 independent experiments. i Levels of mRNASp1 and mRNAp11 in SMNswt that received the indicated treatments for 48 h. Error bars, SEM. *p <
0.05, **p < 0.01, ***p < 0.001; n.s., not significant; by Student's t-test c, d, one-way ANOVA with post hoc Holm–Sidak method a, b, h, i. j The schematic
represents the molecular pathway subserving p11 upregulation under RNS. Source data are provided as a Source Data file
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10 glucose, 3 KCl, 1.25 NaH2PO4, 6 MgCl2, 130 NaCl, and 0.5 CaCl2) and stabilized
at ~37 °C for 1 h. Slices were then transferred to a recording chamber for whole-cell
patch-clamp recordings or to an incubation chamber for treatment with different
drugs before HN microdissection. SMN cultures were prepared from embryonic
day 12.5 (E12.5) mouse spinal cords, as described below.
Recordings of HMNs and SMNs were performed under constant perfusion
(~3–4 ml min−1) with normal oxygenated aCSF at 31 °C. Recordings were obtained
from motoneuron somata, using a Nikon (Tokyo, Japan) Eclipse CFI60 microscope
equipped with infrared differential interference contrast. Patch electrodes (1.5–3
MΩ resistance) were filled with the following internal solution (in mM): 17.5 KCl,
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122.5 K-gluconate, 9 NaCl, 1 MgCl2, 10 HEPES, 0.2 EGTA, 3 Mg-ATP, and 0.3
GTP–Tris at pH 7.4. Recordings were obtained and low-pass Bessel filtered at
10 kHz with a MultiClamp 700B amplifier. Data were digitized at 20 kHz with a
Digidata 1332A analog-to-digital converter and acquired using pCLAMP
9.2 software (Molecular Devices, Foster City, CA). Analysis was only performed for
recordings with access resistance between 5 and 20MΩ. Recordings were discarded
if access resistance changed by >15% during the trial. Series resistance was
routinely compensated 65–75%. The pipette offset potential was neutralized just
before motoneurons were patched. Recordings were not corrected for liquid
junction potential.
In the current-clamp configuration, resting Vm and RN were measured for the
assessment of MN IME. RN was calculated from the current–voltage (I–V) plots
obtained by injecting a series of depolarizing and hyperpolarizing current pulses
(0.5 s; −0.2 to 0.2 nA). In Fig. 1b only the hyperpolarizing square pulses are
exemplified. The resulting data points were then fitted with a regression line, and
RN was estimated as the slope of the lines. Voltage-clamp recordings were all
carried out in presence of tetrodotoxin (TTX, 1 μM; Tocris Cookson, Bristol, UK).
Initially, the holding current (Iholding) required to keep Vm at −65 mV was
measured (Supplementary Fig. 8a). I–V relationships (Supplementary Fig. 8e, right)
were obtained by applying voltage steps in 5 mV increments ranging from −50 to
−120 mV from a baseline holding potential of −65 mV. In this case, the
instantaneous component was measured ~10 ms after the onset of the step
(Supplementary Fig. 8b, e, triangles). In the experiments designed to evaluate
TASK-like pH-sensitive currents, MNs were sequentially recorded at varying pH
levels (pH 6.2, 7.2, and 8.2). Extracellular pH was adjusted adding either HCl or
NaOH to aCSF. TASK-dependent currents (pH-sensitive currents) were obtained
by subtraction of the I–V relationship obtained at pH 8.2 minus that measured at
pH 6.2 (Fig. 5h, Supplementary Figs. 8b and 9b).
Quantitative real-time reverse transcriptase PCR (qRT-PCR). Total RNA was
extracted from medulla, spinal cord, microdissected HNs, dNSC34s, or SMNs
(100,000 cells per well) using the TRIsure Isolation Reagent (BioLine). This pro-
cedure allowed the isolation of total RNA, DNA, and protein fractions from a
single sample. Subsequent treatment with the RNase-free DNase set (Invitrogen),
following the manufacturer recommendations, was performed to reduce DNA
contamination. The concentration and purity of RNA samples were determined by
spectrophotometry at 260 and 280 nm. Retrotranscription (RT) was done using
random hexamers, 500 ng of total RNA as template and iScriptTM cDNA
Synthesis Kit (Bio-Rad). For real-time RT-PCR, each specific gene product was
amplified with the MiniopticonTM System (BIO-RAD), using iQ SYBR Green
Supermix (Bio-Rad). The PCR primers sequences are stated in the Supplementary
Table 1. The cDNA levels for the different samples were determined using the
ΔΔCT method, being gapdh the housekeeping gene. All analyses were performed in
triplicate, with each experiment repeated at least twice.
Western blot analysis. Tissue samples from the medulla, spinal cord or micro-
dissected HNs were homogenized in TRIsure, as above, or in lysis buffer [50 mM
Tris/HCl, pH 7.4, 1% (v/v) Triton X-100, 0.5% (w/v) sodium deoxycholate] sup-
plemented with protease (Sigma-Aldrich) and phosphatase (Pierce) inhibitors
using a 1 ml syringe. dNSC34s cells and SMNs (100,000 cells per well) were rinsed
with ice-cold PBS and immediately transferred to the lysis buffer with protease and
phosphatase inhibitors. Protein concentrations were determined by Bradford-
protein assay (BioRad) or by micro BCA protein assay kit (Thermo Scientific).
Proteins were separated by SDS–PAGE and blotted to polyvinylidene difluoride
membrane (Amersham). Membranes were blocked with BSA 5%, 0.1% Tween for
1 hr at room temperature and subsequently blotted with specific antibodies against
pATF-1 (1:200, Santa Cruz Biotechnology, Cat# sc-7978, RRID:AB_2086020) and
p11 (1:1000, R&D systems, Cat# AF2377, RRID:AB_2183469) developed in goat,
HA (12CA5) (1:50, Sigma-Aldrich, Cat# 11583816001, RRID:AB_514505), RhoA
(1:200, Santa Cruz Biotechnology, Cat# sc-418, RRID:AB_628218), β-actin (1:
2,500,000, Sigma-Aldrich, Cat# A5441, RRID:AB_476744) and α-tubulin
(1:1,000,000, Sigma-Aldrich, Cat# T9026, RRID:AB_477593) developed in mouse,
and Sp1 (1:1,000, Abcam, Cat# ab124804, RRID:AB_10974611), TASK1 (1:200,
Alomone Labs, Cat# APC-024, RRID:AB_2040132; 1:200, Sigma-Aldrich, Cat#
P0981, RRID:AB_260876) or TASK3 (1:200, Alomone labs, Cat# APC-044, RRID:
AB_2039953) developed in rabbit. Proteins were visualized by using horseradish
peroxidase-conjugated secondary antibodies (Pierce) and the enhanced chemolu-
miniscence system (Amersham). Analysis was performed using the ImageJ 1.48 v
software from the National Institutes of Health. Uncropped and unprocessed scans
of all blots are supplied in the Source Data file.
Immunoprecipitation. Immunoprecipitation assays were performed using Pierce®
co-immunoprecipitation kit (Thermo Scientific) following manufacturer’s
instructions with subtle modifications. Briefly, the brain of an adult mouse (CD1)
was mechanically homogenized in immunoprecipitation assay buffer (5 μl/mg of
tissue; 50 mM Tris, 150 mM NaCl, 1 mM EDTA, 1% NP40, and 5% glycerol, pH
7.4 supplemented with a cocktail of protease inhibitors) and cleared by cen-
trifugation. To adjust the protein concentration in samples prior to immunopre-
cipitation, it was measured using a BioRad protein assay kit according to the
manufacturer´s instructions. First, Pierce spin columns containing 25 μl resin were
incubated with 10 μg of anti-p11 antibody (R&D systems) for 3 h in a rotator at
room temperature. As negative control, other spin columns were incubated with
10 µg of an irrelevant antibody (anti-sheep IgG, Sigma-Aldrich) in the same con-
ditions. The homogenates were diluted with immunoprecipitation assays buffer to
have a final volume of 300 μl per column, and incubated with the resins overnight
in a rotator at 4 °C. Resin centrifugation steps were performed at 2000×g for 45 s.
Thereafter, a volume of 60 µl of the elution buffer was passed through every resin to
collect p11 together with their associated-proteins in a first elution (E1) fraction. A
second elution (E2) of 60 µl was collected to ensure that most p11 and p11-
associated proteins were rescued from the resin. For protein denaturalization
100 mM DTT 5× sample buffer was added to eluted fractions which were subse-
quently heated at 95 °C for 5 min. Finally, fractions were subjected to electro-
phoretic and immunoblot analysis for p11 and TASK1 detection.
Primary cultures of SMNs and survival assays. Primary cultures of MNs were
prepared from the spinal cord of mouse embryos at 12.5 days of gestation (E12.5),
following an established protocol65,68. Briefly, desiccated ventral cords were first
chemically (0.025% trypsin in glucose–HEPES buffer solution supplemented with
20 i.u. ml−1 penicillin and 20 mgml−1 streptomycin) and mechanically dissociated
to successively be collected under a 4% bovine serum albumin cushion. Cen-
trifugation (10 min, 520×g) on an Iodixanol density gradient (OptiPrep, Axis-
Shield, Oslo, Norway) allowed to isolate the largest cells, which were once more
centrifuged through a bovine serum albumin cushion. Isolated cells were pooled in
a tube containing culture medium and plated at various densities depending on the
type of experiment. Cultured SMNs were clearly identified by SMI32 immuno-
fluorescence or by morphological criteria. SMNs were cultured in Neurobasal
medium (Gibco, Invitrogen, Paisley, UK) supplemented with B27 (Gibco; Invi-
trogen), horse serum (2% v/v), L-glutamine (0.5 mM), and 2-mercaptoethanol
(25 μM; Sigma-Aldrich), and a cocktail of neurotrophic factors (NTFs): 1 ng ml−1
brain-derived neurotrophic factor, 10 ng ml−1 glial cell-line-derived neurotrophic
factor, 10 ng ml−1 ciliary neurotrophic factor, and 10 ng ml−1 hepatocyte
growth factor (PreProtech, London, UK). Isolated SMNs were plated either in
four-well tissue culture dishes (Nunc, Thermo Fisher Scientific, Roskilde, Den-
mark) for survival experiments (2000 SMNs per well) or on 24-mm Corning glass
coverslips (Corning, NY) placed in 35-mm culture dishes for electrophysiological
experiments (30,000 SMNs per well), Ca2+ imaging (30,000 SMNs per well) or
Fig. 7 Neuroprotective effects of the Sp1-interfering agent Mit-A in the SOD1-G93A mouse model of ALS. a mRNA (left) and protein (right) levels for Sp1
in the spinal cord of SOD1-G93A mice and their Non-Tg littermates at the indicated ages. b Confocal images showing Sp1-immunolabeled nuclei of SMI32-
positive lumbar MNs from 3-month-old Non-Tg and SOD1-G93A mice. Boxed areas in low magnification images for the Non-Tg condition are displayed
at higher magnification together with similar areas obtained from transgenic mice. Box plot represents the mean intensity of nuclear Sp1-labeling of Non-Tg
or SOD1-G93A MNs. c Mechanism of action by which Mit-A might protect neurons against excitotoxic degeneration. d Daily administration of Mit-A
(30 μg kg−1 day−1) in the drinking water, beginning at P30, dysregulated mRNA (left) and protein (right) levels of p11 and TASK1, in the lumbar spinal cord of
SOD1-G93A mice at P120. e Number of SMI32-positive MNs (left), in the L3–L5 spinal cord segment of SOD1-G93A mice and their Non-Tg littermates,
treated with Mit-A or vehicle. Scale bars, 50 μm. f–h Cumulative probability curves of symptoms onset f and survival h, and time course of body weight g,
against the age of SOD1-G93A mice receiving the indicated treatments. Mit-A treatment as in d. i–k Representative electromyographic recordings from the
gastronecmius muscle of Non-Tg and SOD1-G93A mice at weeks 13 i, j and 15 k. Transgenic mice received treatments as in f–h. In i, fibrillation potentials
(dots) were recorded by needle electromyography from a 13-week-old transgenic mouse. These spontaneous muscle discharges were absent in Non-Tg mice
j. l, m Maximal (l) and mean (m) frequency of fibrillations in SOD1-G93A animals at the indicated weeks treated with vehicle or Mit-A. Number of
independent samples is in parentheses. Error bars, SEM. *p < 0.05, **p < 0.01, ***p < 0.001; n.s., not significant; by Student's t-test a, b, d, e, l, m or two-way
ANOVA with post hoc Holm–Sidak method g. Statistic outputs determined by Log-Rank test, Kaplan–Meier analysis f, h or two-way ANOVA g between
treatments are stated on plots. Source data are provided as a Source Data file
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immunocytochemistry (15,000 SMNs per well). For survival evaluation of SMNs,
the cells received complete medium on the seeding day, either containing or
lacking (no NTFs) the combined NTF cocktail. One and four days after seeding,
culture medium with NTFs was replaced with the same medium supplemented
with the experimental conditions (see treatments below). To assess neuronal sur-
vival, the number of large phase-bright cells with long neurites in the total area of
triplicate wells for each condition was counted 72 h after the last treatment. Data
were obtained from at least three independent experiments. Individual symbols in
figures represent a single well. The mean number of surviving cells (in percent) was
normalized taking the “NTF medium alone” treatment as 100%.
Ca2+ imaging. For intracellular Ca2+ measures, isolated SMNs, plated on laminin-
coated coverslips, were washed in Krebs solution (140 mM NaCl; 5 mM KCl; 2 mM
CaCl2; 1 mM MgCl2; 10 mM HEPES; and 11 mM glucose, pH 7.4). Afterwards,
SMNs were loaded with a non-ratiometric or single wave dye that measures free
cytosolic Ca2+. For that purpose, coverslips were incubated (30 min, 37 °C, dark-
ness) in Krebs solution supplemented with Fluo-4 AM (1 μM, Molecular Probes,
Invitrogen) and pluronic acid (0.02%). Confocal images were obtained by means of
a direct Olympus FV1000 confocal laser scanning microscope using a ×40 water
immersion objective. Fluo-4 AM was excited at a wavelength of 488 nm and the
emission fluorescence at a wavelength of 518 nm was acquired for offline analysis.
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Time-lapse images were taken at 5-s intervals for at least 50 min. All experiments
were performed at 31 °C. For the analysis of Ca2+ dynamics, regions of interest
including overall SMN somata were used and the background was subtracted from
each selected SMN. SMN Ca2+ concentrations were estimated using the maximal
fluorescence equation:
Ca2þ
 
i¼ Kd ´ F=Fmax1=Rf
 
= 1 F=Fmax
 
where Kd is the Fluo-4 AM dissociation constant, that in our experimental
conditions was 273.2 nM, and Rf is the dynamic range of Fluo-4 AM for each
analyzed SMN (Fmax/Fmin). F was the recorded fluorescence. Fmax and Fmin values
were determined, at the end of each experiment, by exposing SMNs to the Ca2+
ionophore ionomycin (10 μM) and subsequent addition of the Ca2+ chelator,
EGTA (15 mM), respectively. Kd and Rf values for our experimental conditions and
cell types were estimated in vitro by using standard methods69.
Nerve injury models. Rat pups (P3) and adult mice (>2-month-old) were sub-
jected to XIIth nerve crushing or partial resection, respectively. Both modalities of
nerve injury induce neuronal hyperexcitability preceding motoneuron loss mainly
by glutamate-induced excitotoxicity10. Anesthetized animals (1.5–3% isoflurane
mixed with 100% O2) received intramuscularly atropine (0.2 mg kg−1) and dex-
amethasone sodium phosphate (0.8 mg kg−1). The absence of withdrawal reflexes
was considered a signal of sufficient deep anesthesia. In P3 rats, the right XIIth
nerve was isolated from the surrounding tissue and the common nerve trunk was
thoroughly crushed with microdissecting tweezers, applied for 30 s (Fig. 5f, Sup-
plementary Fig. 9f). In adult mice, following nerve isolation, a 2-mm segment was
surgically removed (Fig. 4c). Both types of lesion were performed just proximal to
the bifurcation of the main XIIth nerve trunk into lateral and medial branches. In
adult mice, axonal regeneration, from the proximal stump of the injured nerves,
was minimized by a tied suture thread (3/0). The incision was sutured and cleaned
with an aseptic solution (povidone-iodine). The animals were sacrificed at different
time points after nerve injury, depending on the experimental paradigm. All ani-
mals received one post-operative injection of penicillin (20,000 i.u. kg−1; i.m.) to
prevent infection and pirazolone (0.1 mg kg−1; i.m.) for post-surgery analgesia.
Histological analysis. Animals, under deep anesthesia (7% chloral hydrate), were
intraventricularly injected with heparin and immediately perfused transcardially
with phosphate buffered saline (PBS), followed by 4% paraformaldehyde (PFA) in
0.1 M phosphate buffer (PB), pH 7.4, at 4 °C. The medulla and/or lumbar spinal
cords (L1–L3 or L3–L5) were rapidly dissected and postfixed for 2 h in 4% PFA.
Cryoprotection was performed by immersion in 30% sucrose in 0.1 M PB (4 °C,
overnight). Serial coronal sections (30 μm-thick), obtained by means of a micro-
tome, were kept at −20 °C in a cryoprotectant solution (glycerol/PBS, 1:1 v/v) until
processing.
For immunohistochemistry, after PBS washing, sections were immersed in a
blocking solution [2.5% (w/v) bovine serum albumin, 0.25% (w/v) sodium azide,
and 0.1% (v/v) Triton X-100 in PBS] for 30 min, followed by incubation (4 °C,
overnight) with the polyclonal primary antibodies against SMI32 (1:8,000; Covance
Research Products Inc, Cat# SMI-32R-500, RRID:AB_509998), GFAP (1:250; Santa
Cruz Biotechnology, Cat# sc-58766, RRID:AB_783554) developed in mouse, Sp1
(1:50, Abcam, Cat# ab124804, RRID:AB_10974611), TASK1 (1:200, Alomone Labs,
Cat# APC-024, RRID:AB_2040132) developed in rabbit, and p11 (1:50, R&D
systems, Cat# AF2377, RRID:AB_2183469) developed in goat. Next, the tissue was
rinsed with PBS and incubated for 1 h at room temperature with Cy2-conjugated,
Cy3-conjugated, and/or Cy5-conjugated, or biotinylated anti-goat, anti-mouse,
and/or anti-rabbit IgGs (1:400; Jackson ImmunoResearch Laboratories) as
secondary antibodies. When applicable, biotin was detected by means of the
avidin–biotin–peroxidase system (Pierce, Rockford, IL, USA) using as chromogen
3,3-diaminobenzidine tetrahydrochloride. Sections were mounted on slides,
dehydrated, covered with DePeX, and visualized under light microscopy. Sections
were analyzed using an Olympus IX81 inverted microscope for light microscopy or
an Olympus FV1000-MPE confocal microscope for fluorescence microscopy
(Olympus, Japan). Images were acquired through a z-plane in which maximum
antibody penetration was evidenced. The pinhole opening was 1 Airy unit. For
comparison between different experimental conditions, acquisition setting was kept
identical. Animals and tissue were processed in parallel. Images were processed for
background subtraction to obtain the maximum dynamic range of greyscale (from
0 to 250) and analyzed using the software provided by Olympus. In all cases, the
area delimiting p11-positive or TASK1-positive somata or Sp1-immunoreactive
nuclei were manually traced, and for each cell, the mean optical density (o.d.) or
fluorescence intensity was measured. MNs were acquired in sections obtained from
at least three animals per condition. Treatments were blinded for researcher who
performed measures.
For Nissl or neutral red staining, brainstem sections containing the HN were
mounted on slides, re-hydrated, and immersed in Nissl (10 min, 0.5% cresyl violet)
or red neutral (5 min, 1% neutral red in 0.2 M acetate buffer, pH 3.3) staining
solutions. The sections were then rinsed with distilled water, dehydrated in ethanol,
cleared in xylene, and covered with DePeX.
The number of neurons with a well-defined nucleus was quantified in one of
each three serial sections through the whole rostrocaudal extent of the HN or in
one of each three–six serial sections through the L1–L3 or L3–L5 segments of the
lumbar spinal cord. SMI32-identified MNs were counted in 10 horizontal or 30
coronal sections of the lumbar spinal cord from 4-month-old mice. All
quantifications were carried out by researchers blinded to the lesion side, treatment
and/or genotype groups.
SMNs, plated in four-well tissue culture dishes (15,000 cells per well), were
processed by double-immunostaining for p11 and TASK1. At 3–4 DIV, cRNA-
treated and siRNAp11-treated SMN cultures were fixed in 4% PFA (15 min, room
temperature) and 100% methanol (10 min, 4 °C) and incubated overnight at 4 °C
with polyclonal antibodies against p11 (1:100) and TASK1 (1:100) developed in
goat and rabbit, respectively. SMNs were further incubated with goat and rabbit
anti-IgG secondary antibodies conjugated with Cy3 and Cy2 (1:200; Jackson
ImmunoResearch Laboratories), respectively. Dishes were analyzed using a Leica
(Nussloch, Germany) confocal fluorescence microscope. Images were acquired
through the z-plane containing the highest density of large diameter SMNs and
well defined neurites as above. The pinhole opening was 1 Airy unit. Acquisition
settings were identical for cRNA and siRNA-treated cultures, which were
processed and acquired in parallel. Images were captured and processed for
background subtraction to obtain the maximum dynamic range of intensities
(from 0 to 250) and analyzed using the software provided by Leica. In all cases, the
area delimiting somata and neurites was automatically traced by applying a macro,
and for each image, the integrated and mean immunofluorescence intensities of
SMN cell bodies and neurites were obtained in both the cRNA-treated and
siRNAp11-treated cultures.
Lentiviral constructions. All neuron-specific LVVs used in this work were
designed, constructed, and produced under the supervision of Dr. S. Kasparov
(Bristol University, Bristol, UK) during a research stay of G.R.B. in his lab. All the
lentiviral constructions were made based on the vector pTYF-mCMV/SYN. This
system uses a transcriptional amplification strategy (TAS) to bidirectionally
enhance the transcriptional activity of human synapsin-1 (SYN) promoter, by
joining upstream a minimal core promoter (65 bp) derived from the human
cytomegalovirus (mCMV) in the opposite orientation. This construction creates a
compact TAS-amplified neuron-specific promoter useful for the development of
powerful gene expression systems70. Two cloning steps were necessary to generate
the LVV-shRNAlacz plasmid. First, the shRNAlacz sequence (5′-AAATCGCTGA
CTTGTGTAGTCGTTTTGGCCACTGACTGACAACCACACATCAGCGAT
TT-3′) was cloned into the vector pcDNA6.2-WemGFP (Invitrogen) to obtain the
shRNAlacz-GFP (green fluorescent protein) plasmid. Finally, a PCR product con-
taining the shRNAlacz-GFP was cloned into the vector pTYF-CMV/SYN70 to
Fig. 8 TASK1-dependent neuroprotective effects of Mit-A in the traumatic model of MN degeneration. a–c Effects of resection of a 2-mm-segment of the
XIIth nerve on mRNASp1 and Sp1 levels a, number of Sp1-immunoreactive nuclei b, and optical density of nuclear staining c in the HN of the injured (inj)
versus the intact (int) side at the stated days post-lesion. Coronal sections immunolabelled for Sp1 b, c, some of them counterstained by Nissl (c, bottom),
obtained 7 days after nerve injury. At least 50 Sp1-immunoreactive nuclei per animal and side were analyzed in c. d Immunoblots for Sp1 from HNs of the
intact and injured sides at 7 days post-lesion in mice treated with L-NAME (180mg kg−1 day−1, i.p.) or its inactive stereoisomer D-NAME from day 5th
after nerve resection. gapdh and α-tub/β-act were internal controls for qRT-PCR and western blotting, respectively. e, f Plots represent the number of
neurons (in percent) in the injured versus the intact side taken as 100%. In e, administration of vehicle and drugs were intraperitoneal (i.p.). Mit-A was
orally administered except when indicated as i.p. applied in f. Nissl stained coronal sections obtained from mice sacrificed 3 weeks after nerve injury
receiving indicated treatments are shown to the left in f. Dotted lines delimit the HN in each section. Animals treated with vehicle in e and vehicle i.p. in f
are the same. f Control, untreated animals; vehicle, drinking water supplemented with 1% sucrose; Mit-A-30 (30 μg kg−1 day−1); Mit-A-300 (300 μg kg−1
day−1). Note that Mit-A was neuroprotective for task3−/−, but not for task1−/− mice. Scale bars, b 350 μm; c 100 μm; f 500 μm. Number of independent
samples is indicated in parentheses. Error bars, SEM. *p < 0.05, **p < 0.01, ***p < 0.001; n.s., not significant; by paired (injured vs. intact side within a
treatment, a–f), unpaired (comparison between two groups, f) Student t-test or one-way ANOVA with post hoc Holm–Sidak method (comparison between
more than two treatments, e, f). Source data are provided as a Source Data file
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generate the final lentiviral plasmid. This same procedure was also followed to
obtain the LVV-shRNAp11 plasmid using the shRNAp11 sequence (5′-TAGTCA
TTGCATGCAATGGTGGTTTTGGCCACTGACTGACCACCATTGTGCAATG
ACTA-3′).
A different strategy was used to generate the LVV-dnSp1 vector. The full cDNA
sequence for the Sp1 dominant negative71 corresponding with the C-terminal
domain of the consensus sequence (622–788; a gift from Dr. Johann Rotheneder,
Medical University of Vienna, Austria) was cloned into the pIRES2-eGFP. A PCR
product containing the dnSp1-eGFP sequence was cloned into pTYF-mCMV/SYN
plasmid to generate the final LVV-dnSp1 construction.
Transient co-transfection of HEK293FT cells with shuttle plasmids, the
packaging vector pNHP, and the envelope plasmid pHEF-VSVG was performed
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to produce the LVV plasmid system derived from HIV-1 used for this study70.
The virus-containing medium was harvested 48 or 72 h after transfection
and filtrated using a 0.45 μm filter (Millipore). Filtrated medium was carefully
added on the top of a 20% sucrose solution and subsequently centrifuged at
75,000×g for 2 h. After removal of the supernatant, the pellet was re-suspended
in PBS.
Finally, the titer of the virus (>109 iu μl−1) was determined using the ELISA kit
Lenti-X p24 rapid Titer (Clontech) which measures the amount of lentiviral capsid
protein p24. Cells were transduced with the different LVVs at a five times
multiplicity of infection.
Plasmid constructions, deletions, and site-directed mutagenesis. The pro-
moter region of the p11 human gene (about 1.4 kb of the gene 5′ flanking region)
was amplified using primers designed to add complementary overhangs in BglII-
HindIII and the bacterial artificial chromosome (BAC) RP11-139D23 as genomic
DNA template (developed by Dr. Kazutoyo Osoegawa, and acquired through the
BACPAC Resource Center, Children’s Hospital Oakland Research Institute,
California, USA). PCR conditions used were 95 °C 5min, (95 °C 30 s, 52 °C 30 s,
72 °C 1min) × 35 cycles, and 72 °C 5min for final extension. The PCR amplicon
was purified using a PCR Purification Kit (Qiagen), digested with BglII-HindIII
and cloned into the pGL4.10 luciferase Firefly reporter plasmid (Promega) in BglII-
HindIII to generate −1436+ 89p11-Fir (pGL4.10-p11-Fir) construct. The human
promoter sequence was confirmed by sequencing.
To narrow down NO-responsive regions in the promoter sequence, we
performed serial 5′ deletions of the promoter by PCR, changing the 5′ sense
primer. The common+89 HindIII 3′ primer was 5′-AAGCTTACCTTGGCCG
AGGCGCGGCG-3′. Primers used for 5’ deletions of the p11 promoter were as
indicated in Supplementary Table 1. The amplicons were cloned into pGL4.10 as
above. When these regions were identified, we looked for transcription factors with
ability to bind to the delimited promoter segments using a virtual transcription
element search system. Site-directed mutagenesis of the transcription factors’
binding sequences were then performed by PCR.
For site-directed mutagenesis, modified versions of the −96 fragment 5′ primer
were used to develop PCR. The related primers used were as indicated in
Supplementary Table 1.
Luciferase reporter assay. dNSC34 cells were transiently co-transfected with 5 μg
of the different constructs cloned in pGL4.10-Fir and 0.5 μg of the wild-type Renilla
luciferase control reporter vector pGL4.74-Ren (Promega) to determine the
transfection efficiency, using the calcium phosphate precipitation method. 40,000
dNSC34s per well were transfected. After 24 h in the transfection medium, this
medium was washed out and replaced by culture medium supplemented with
diverse drugs. Finally, luciferase activity was measured using the Dual-luciferase
Reporter Assay System (Promega). Promoter activity was measured in relative
units of luciferase (RUL) of Firefly versus Renilla activities and normalized to the
control.
Undifferentiated NSC34s (CELLutions Biosystems Inc., Toronto, Canada) were
cultured in high glucose Dulbecco’s modified Eagle’s medium (DMEM),
supplemented with 10% (v/v) fetal calf serum (FCS), 2 mM L-glutamine and 1%
(v/v) penicillin/streptomycin. To induce maturation, NSC34s were plated at low
density (4,000 cells cm−2) in 1:1 DMEM plus Ham’s F12 medium supplemented
with 1% (v/v) FCS, 1% penicillin/streptomycin, and 1% modified Eagle’s medium
non-essential amino acids (Sigma-Aldrich)65. Differentiated phenotype of these
cells was visually verified after 7–9 days in differentiating medium and
transfections were carried out as above.
Electrophoretic mobility shift assays. Nuclear extracts were isolated from
~4 × 106 dNSC34 cells. dNSC34s were gently washed in PBS and collected by
centrifugation in a microcentrifuge at 8,600×g. Cells were re-suspended in isotonic
buffer (10 mM Tris–HCl pH 7.5, 2 mM MgCl2, 3 mM CaCl2, 0.3 M sucrose, 1 mM
DTT) plus a protease inhibitors cocktail (Sigma). Next, plasma membrane was
disaggregated in a 10% NP40 solution and the total mix was centrifuged at 8,600×g
(30 min, 4 °C). Subsequently, the pellet was re-suspended in extraction buffer
[20 mM Hepes pH 7.9, 1.5 mM MgCl2, 0.42M NaCl, 0.2 mM EDTA, 25% Glycerol
(v/v)]. After further centrifugation (14,200×g, 10 min, 4 °C), the resultant super-
natant, enriched in nuclear proteins, was aliquoted.
Double stranded probes were obtained by mixing equal volumes of both
complementary primers (wild-type and Mut 5; Supplementary Table 1) at
equimolar concentration (25 μM). We next placed the tube in a standard heat-
block at 90–95 °C for 3–5 min followed by cooling at room temperature overnight.
Then, the probes were 5′-labeled by a T4 Polynucleotide Kinase (Promega Gel Shift
Assay System) using [γ32P]-ATP (3,000 Ci mmol−1 at 10 mCi ml−1). Labeled
probes were purified by spin-column chromatography (Microspin™ G-50 Columns,
GE Healthcare).
Binding reactions between the nuclear extracts and radiolabeled probes were
performed by incubating 1 μl of nuclear extract, 4 μl of binding buffer (50 mM
Tris–HCl pH 7.5, 250 mM NaCl, 5 mM MgCl2, 2.5 mM EDTA, 2.5 mM DTT, 20%
Glicerol), and 1 μl of poly (dI-dC)/(dI-dC) (1 μg μl−1 in 10 mM Tris–HCl, pH 7.5,
1 mM EDTA) in the presence or absence of competitor oligonucleotides or
antibodies [anti-Sp1 (2 μg μl−1), Abcam, Cat# ab124804, RRID:AB_10974611, or/
and anti-Sp3 (2 μg μl−1), Santa Cruz Biotechnology, Cat# sc-13018, RRID:
AB_2194471]. Nuclear extracts were pre-incubated for 1 h at 4 °C with antibodies
or with oligonucleotides comprising the canonical sequence for Sp1 (5′-
ATTCGATCGGGGCGGGGCGAGC-3′; 1.75, 3.5 and 5.25 pmol μl−1) or AP-2 (5′-
GATCGAACTGACCGCCCGCGGCCCGT-3′; 5.25 pmol μl−1) before adding the
radiolabeled probe for 25 min at RT. Products were electrophoresed at 30 mA for
3 h on 4.8% polyacrylamide gels in high ionic strength buffer (50 mM Tris, 380 mM
glycine, 2 mM EDTA, pH 8.5). Dried gels were analyzed by autoradiography
[Personal Molecular Imager™ (PMI™) System, Biorad].
Evaluation of disease progression in SOD1-G93A mice. Transgenic males were
received at pre-symptomatic stage (P30). Then, habituation sessions for rotarod
and grip strength began at P45. One or two valid measures were obtained before
cannula implantation for chronic oligonucleotide administration at P60 to discard
surgical effects on motor performance. Only animals with no evident motor deficits
at one week after surgery were included in the study. Researchers blinded for
treatments did all behavioral studies.
Surgery to implant the cannula infusion system (Plastics One Inc., Roanoke,
VA, USA) for intracerebroventricular chronic administration of oligonucleotides
was performed in 2-month-old animals. Briefly, under general anesthesia (as
above), mice were fixed with ear bars in a stereotaxic frame and the skin was
incised longitudinally after shaving and disinfecting. The guide cannula and its
respective dummy cannula were carefully advanced throughout a drilled round
window (0.5 mm in diameter) in the midline of the interparietal–occipital bones
junction. Cannula was placed in parallel and close to the inner portion of the
occipital bone (Fig. 3g). The infusion system was finally attached to the skull by
means of acrylic resin once the end of guide cannula was positioned near to the
fourth ventricle. To gain in stability and endurance, all the system was cemented
with the same resin to two screws fixed in the left and right parietal bones. Post-
operative cares were as above.
The body weight for each mouse was weekly recorded, beginning one week after
surgery. Individual weights were normalized taking the mean value of initial
measures as 100%. At the beginning of the study (66 days), mean body weight was
similar for the two cohorts (cRNA: 23.4 ± 0.5 g; siRNAp11: 24.2 ± 0.4 g; p= 0.124,
Student t-test). Survival times were analyzed by means of Kaplan–Meier survival
analysis with Log-Rank tests for statistical significance. The end stage was defined
as the day when mice were unable to right themselves 30 s after being placed on a
side. At this time point, animals were euthanized using a carbon dioxide-enriched
atmosphere.
Fig. 9 Cell-type specific p11 knockdown is neuroprotective for MNs in the SOD1-G93A mouse model of ALS. a Bilateral microinjections of neuron-specific
LVVs were performed in the ventral horn of 2-month-old SOD1-G93A mice (see schematic on top). Reference section (from the Allen Brain Atlas)
illustrating injection protocol (left) is the same than in Fig. 3a. Bright-field (middle panels) and fluorescence (right panels) images of the same coronal
sections showing injection places (boxed areas) of Chicago sky blue at the same coordinates than LVVs. Insets, details of injection places. b Representative
acetyl-cholinesterase (AChE)-immunostained L1–L3 sections (from the Allen Brain Atlas) showing horizontal plane sectioning performed to analyze LVV-
treated mice. c–e Confocal images showing p11 immunolabelled GFP-positive SMI32-identified lumbar MNs from 4-month-old SOD1-G93A mice after
intraspinal microinjection of LVV-shRNAlacz c, LVV-dnSp1 d or LVV-shRNAp11 e performed in 2-month-old animals. Note that while glial-like structures
(arrows) show similar p11 labeling intensity in all conditions, transduced MNs in d and e display considerably less intensity than in c. f Mean fluorescence
intensity (arbitrary units, a.u.) of p11 staining in GFP−/SMI32-positive lumbar MNs. g, h Representative SMI32-immunostained ventral horn (L1–L3)
horizontal sections obtained from 4-month-old mice of the stated genotypes receiving indicated treatments. High magnification photomicrographs of some
vacuolated MNs (arrows) are shown. Scale bars, a 500 μm; c–e 50 μm; g, h 20 and 100 μm, high and low magnification images, respectively. i Number of
MNs in the L1–L3 spinal cord segment of 4-month-old mice with the indicated genotypes that received the stated treatments. Number of independent
samples is in parentheses. Error bars, SEM. *p < 0.05, **p < 0.01, ***p < 0.001; n.s., not significant; by one-way ANOVA with post hoc Holm–Sidak method.
Source data are provided as a Source Data file
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-11637-4 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:3784 | https://doi.org/10.1038/s41467-019-11637-4 | www.nature.com/naturecommunications 19
Evaluation of motor function was assessed by rotarod, footprint, runtime, and
grip strength tests. Rotarod test was carried out to judge motor coordination,
strength, and balance. Animals were daily trained for one week before data
acquisition. Mice were placed individually on a cylinder (3.4 cm in diameter),
rotating at a constant speed of 15 rpm. The longest latency without falling for each
animal was recorded once per week, after three attempts to keep onto the rotarod
(Rotarod LE8500, Panlab SA, Barcelona, Spain). Rotarod recordings began one
week before surgery and an additional test was performed one day before surgery.
The cut-off time was taken at 180 s. As starting point to construct the cumulative
probability curve of symptoms onset, we used the first day in which a mouse
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Fig. 10 Schematic diagram modeling the role of the Sp1–p11–TASK1 triad in neurodegeneration. a Physiological expression of the transcription factor Sp1
maintains baseline levels of p11, which regulates IME by controlling TASK1 trafficking from the endoplasmic reticulum (ER) to the plasma membrane.
p11–TASK1 complex dissociation is required to overcome ER retention and normal recycling of TASK1 to the surface14. Under healthy conditions, when
neuronal IME is fine-tuned, moderated Ca2+ influx, through GluRs and/or VSCCs, leads to physiological responses, which are controlled by mechanisms of
intracellular Ca2+ buffering and extrusion. b In neurological conditions, over-expression and/or de novo expression of nNOS could be the switch on (star)
to initiate a positive feedback loop that contributes to the degeneration and death of sick neurons. Usually, NO production in the nervous system is directed
by Ca2+ influx driven by NMDA receptors. The calmodulin (CaM)–Ca2+ interaction, which is now enabled to activate nNOS, allows for the coupling of
pathological NO synthesis to Ca2+ entry. NO reacts rapidly with the superoxide anion (O2−) to form the highly toxic product peroxynitrite (ONOO−) and/
or promotes S-nitrosylation, triggering protein misfolding and aggregation, thus leading to neurotoxicity8 (omitted for simplicity). In addition, a persistent
pathological concentration of NO, involving the sGC/PKG-RhoA/ROCK pathway (omitted for simplicity), induces Sp1 and stimulates the human p11
promoter depending on, at least, a Sp1-binding site (GC-box). Subsequent p11 upregulation sequesters TASK1 to the ER, thus disrupting the normal
recycling of this subunit to the surface. This TASK1 uptake/replenishment unbalance enhances IME, which, in turn, increases the opening probability of
VSCCs and, GluRs in the presence of glutamate, thereby exacerbating Ca2+ entry into the cell. Ca2+ overload might contribute to neurodegeneration and,
finally, to neuron death. Whether NO of glial origin6 and/or other unidentified factors promote Sp1 expression/binding and/or p11 expression are not
discarded and merit for further investigation
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showed motor function deficits on the rotarod test (≥10% reduction in the time to
fall) followed by progressive deterioration in performance in the next sessions.
Footprint analyses for step length and runtime were performed weekly starting
one week after surgery. The hind feet were immersed into innocuous black ink and
animals were placed on a conventional calibrated paper along a gangway of 50 cm
length. Footprints were analyzed with respect to the step length as illustrated in
Supplementary Fig. 6e. Additionally, the time duration required by the mice to run
along the track was determined.
Muscle strength of forelimbs and hind limbs was monitored on a grip strength
meter (Grip Strength Meter, BIOSEB, Chaville, France) twice a week for each mouse.
The animal held by the tail, once ensured that its fore-limbs or hind-limbs were
gripping a T-bar or a grid, respectively, were pulled upwards at a 60° angle. The grid
and T-bar were connected to a force transducer and grip strength was measured in
grams. The highest outcome of three trials per mouse was recorded for each session.
Mean value per week for each mouse was taken to construct time course of grip
strength for the two cohorts, cRNA-treated or siRNAp11-treated SOD1-G93A mice.
Electromyography was performed by inserting a concentric needle electrode
into the gastrocnemius muscle of anaesthetized mice (1.5% isoflurane mixed with
100% O2). To ground the system, a monopolar needle electrode was inserted into
the tail of the mouse. The electrical signals were amplified and filtered at a
bandwidth of 10 Hz–10 kHz for display and digitization purposes. Spontaneous
activity of the muscle was monitored and recorded for 30 min, after a period of
5 min of stabilization. Only spontaneous activity with an amplitude of at least
50 μV was considered as a significant signal. Mean and maximum frequency of
fibrillation potentials were calculated from automatically selected 1 s-intervals all
along the recording session (30 min). Thus, 1,800 data per animal and session were
used to construct box-plots (Fig. 7l, m).
Drugs and treatments. SMN cultures were treated at different DIV depending on
the experimental series. Oligonucleotides (cRNA, siRNAp11; 2 μM each) and LVVs
(LVV-shRNAlacz, LVV-shRNAp11, LVV-dnSp1; 2 μl in 350 μl of culture medium)
were added to the culture medium at 1 DIV, and were washed out at 4 DIV. For
patch-clamp recordings, SMNs (4 DIV) were initially perfused with normal aCSF
to obtain baseline control data. Next, SMNs were superfused for 10 min with aCSF
containing AEA (3 or 10 μM) before voltage responses were acquired again. Finally,
a last round of acquisition was taken after a 10 min washout with AEA-free aCSF
(Fig. 2f). For survival experiments, bupivacaine (40 μM, 60 min), isoflurane
(0.8 mM, each 10 min for 70 min), AEA (0.03, 0.05, 0.1, 1, 3, 5 or 10 μM, 30 or
60 min), ethanol (0.07%, v/v, 60 min), AM281 (0.5 μM, 65min), AEA+AM281,
alone or in combination with glutamate (150 μM, 30min) were added to the
culture medium at 4–5 DIV (Fig. 2d, e, h, Supplementary Fig. 4c,d). For Ca2+
imaging experiments, Fluo-4-charged SMNs were initially perfused (~5 min) with
Krebs solution to obtain resting [Ca2+]i. Next, nifedipine (30 μM), ω-conotoxin
GVIA (0.5 μM), ω-agatoxin IVA (0.1 μM), NBQX (20 μM), or (DL)-APV (50 μM)
were added, for at least 5 min or until a new plateau was reached. Then, glutamate
(150 μM) was co-added to the solution for 30 min. The Sp1-interfering agent Mit-A
(30 nM, Serva Electrophoresis GmbH, Heidelberg, Germany) was added to the
culture medium at 3 DIV for 24 or 36 h. Although, it cannot be fully discarded that
Mit-A may impair the binding of another transcription factors with affinity for
GC-rich sequences, here, we used this drug as a prospective pharmacological
strategy with clinical potential for reducing, at least, Sp1 function.
dNSC34 cultures, after 7–9 days in differentiating medium, were treated with
the following drugs: the broad-spectrum NOS inhibitor Nω-nitro-L-arginine methyl
ester (L-NAME, 100L μM, 48 h) or the inactive stereoisomer D-NAME (100 μM,
48 h); the long half-life NO donor (Z)−1-[2-(2-aminoethyl)-N-(2-ammonioethyl)
amino]-diazen-1-ium-1,2-diolate-NO (DETA/NO) (0.03, 0.1, 0.5, 1 or 2 mM; 6, 12,
24, 48 or 72 h) or DETA (1 mM, 48 h); the specific soluble guanylyl cyclase (sGC)
inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ; 20 μM, 48 h; Sigma-
Aldrich); the specific protein kinase G inhibitor (PKG-i) guanosine, 3′,5′-cyclic
monophosphorothioate, 8-4-chlorophenylthio-, Rp-isomer (Rp-8-pCPT-cGMPS;
10 μM, 48 h; Calbiochem); the specific inhibitor of ROCK (S)-(+)−2-methyl-1-[(4-
methyl-5-isoquinolinyl)sulfonyl]-hexahydro-1H-1,4-diazepine dihydrochloride
(H1152; 20 μM, 48 h; Tocris Bioscience); and Mit-A (30 nM, 48 h). DETA was
obtained by adding DETA/NO (1 mM) to culture medium 48 h before treatment.
At that time, almost all NO had been already released from DETA/NO. DETA/NO
(1mM) was also co-added together with ODQ, PKG-i or H1152 in some
experiments.
Brainstem slices, at the level of the HN, were incubated with different
combinations of drugs according to the aim of each experimental series (see above
and main text). For patch-clamp recordings, drug treatments were either acute
(10–25 min during patch-clamp recordings) or “chronic” (a minimum of 4 h before
the recordings and during the recordings). To study expression levels of diverse
molecules, drugs were applied for 6 h before HN microdissection. Control slices
were for the same time period in standard aCSF. Acute treatments were as follow:
the Gαq inhibitor YM-254890 (1 μM, 25 min; kindly provided by Astellas Pharma
Inc., Tokyo), thyrotropin-releasing hormone (TRH) (10 μM, 10–15 min), the
specific inhibitor of ROCK trans−4-[(1 R)-1-aminoethyl]-N-4-
pyridinylcyclohexanecar boxamide dihydrochloride, Y27632 (10 μM, 15 min) were
applied after chronic incubation with DETA/NO (1 mM, ≥ 4 h; Supplementary
Fig. 8c). Drug combinations for chronic treatments were as follow: DETA/NO
(1 mM), DETA/NO+PKG-i (10 μM), DETA/NO+H1152 (20 μM), DETA/NO+
Y27632 (10 μM), DETA/NO+YM-254890, the Rho inhibitor C3 exoenzyme (C3
exo, 2.5 μg ml−1), DETA/NO+C3 exo, dexamethasone (Dexa, 1 μM), retinoic acid
(20 μM), DETA/NO+retinoic acid, L-NAME (100 μM).
Neonatal rats received a daily subcutaneous injection of L-NAME (90 mg kg−1
day−1) beginning on the day of nerve crushing. Alternatively, rat pups (P5)
received a single injection of oligonucleotides65. Anesthetized animals (as above)
were placed in a stereotaxic instrument (David Kopf Instruments, Tujunga, CA).
siRNAp11 or non-targeting siRNA (cRNA) (2 μg per rat; Accell, Dharmacon Inc.,
Lafayette, CO) in 2 μl of RNase-free PBS was injected at a rate of 0.5 μl min−1 by
means of a microsyringe (5 μl, Hamilton Company, Tokyo, Japan). Chemically
modified siRNA used here has been reported to reduce the expression of target
genes in neurons, but not glia, after intracerebroventricular administration72. The
needle ending was visually guided by means of a surgical microscope to deliver
oligonucleotides into the fourth ventricle. The target sequence for the siRNAp11 was
5′-CUUCUGAGUUUUAUAUUGU-3′. Brainstem slices of treated rats were
quickly extracted at P6–P8 for electrophysiological studies as above.
Adult mice (2-month-old) received a first intracerebroventricular injection of
cRNA (5 μg per 5 μl) or siRNAp11 (5 μg per 5 μl), in siRNA buffer (Dharmacon),
just after implantation of the cannula infusion system. Oligonucleotides
administration was weekly repeated under light anesthesia (0.5–1.0% isoflurane
mixed with 100% O2) just to avoid unexpected sudden movements of the animal
during infusion. An infusion cannula with the appropriated outer diameter was
filled with 5 μl of oligonucleotide-containing solution. Intracerebroventricular
microinjection of the solution was performed slowly for a period of 10 min driven
by an oil-filled tubing system connected to a Hamilton syringe. After the injection,
the cannula was left in place for 5 min and then slowly retracted. Sham mice were
similarly implanted with the chronic injection system and, weekly manipulated as
the experimental group, but volume delivery was omitted.
In another experimental series, adult mice under deep anesthesia (as above)
were placed in a stereotaxic device and surgically prepared to receive a single
injection of LVVs or vehicle (sterile PBS)73. Briefly, a midline dorsal incision
exposed the caudal dorsal medulla and, subsequently, glass micropipettes (∼25 μm-
tip diameter), connected to an oil-filled system, were visually advanced to perform
microinjections of the LVVs (Fig. 4c). p11 upregulation in the HN began as soon as
1 day after XIIth nerve transection. In order to minimize feasible harmful effects of
p11 upregulation, LVVs were microinjected 3 days before nerve injury since a delay
of 3–4 days is expected for effective action of shRNAp1170. Furthermore, this
schedule increases the rate of success of the experiment with the aim to minimize
the number of animals required. LVV injection into the HN involves a longer-
lasting and more aggressive surgical approach than resection of the XIIth nerve.
Therefore, to optimize experimental successfulness, we performed nerve
transection in animals in which LVV application did not compromise animal
integrity beyond that expected from surgery. Three days before nerve injury, a
microinjection (0.5 μl) of LVV-shRNAlacz, LVV-shRNAp11, or the vehicle was
performed in the midline and 0.7 mm below the dorsal surface of the medulla at
the obex level. The intramedullar injection rate was 0.1 μl min−1 and the
micropipette remained in situ for 10 min before being slowly withdrawn at the end
of injection. The incision was sutured and cleaned with an aseptic solution
(povidone-iodine). 24 days after lentiviral infusion, animals were processed for
mRNA and protein extraction or for histological inspection as described above.
In addition, 2-month-old SOD1-G93A mice were anesthetized and placed in a
stereotaxic frame to perform intraspinal microinjections of LVV-shRNAlacz, LVV-
shRNAp11, or LVV-dnSp1. The L1–L2 lumbar segment was exposed by
laminectomy. Then, two microinjections (0.5 μl each, 2-mm-apart in the
rostrocaudal axis) per side of LVV-containing solutions were carried out, as above,
at 0.4 mm lateral to the midline and 1 mm below spinal cord dorsal surface
(Fig. 9a). To verify the injection place, some wild-type animals received the same
volume at the same coordinates of a 2% solution of Chicago sky blue 6B (Sigma) in
PBS (Fig. 9a).
For treatment with Mit-A or Riluzole (Sigma-Aldrich, St. Louis, USA), drugs
were dissolved in sterilized drinking water supplemented with sucrose (1%). Each
animal received daily 5 ml of the drug/vehicle solution to assure that each mouse
received the appropriated dosage (Mit-A, 30, 150, 300, or 3000 μg kg−1 day−1;
Riluzole, 25 mg kg−1 day−1). Vehicle (1% sucrose) and Mit-A or Riluzole
containing solutions were freshly prepared each 3 days. Combined treatment with
Mit-A and Riluzole did not lead to additive or synergistic effects (not shown).
Statistics. Summary data are all presented as mean ± s.e.m. The number of ana-
lyzed specimens per experimental paradigm, and statistical tests applied to each
data set are indicated in figure legends or in the “Results” section. Statistical
analysis was performed using SigmaPlot (Systat Software, Inc.). The minimum
significance level was set at p < 0.05. Statistical tests were employed for all data sets
with similar variance. For comparison between two groups, normally distributed
data were analyzed by unpaired Student's t-test, unless otherwise stated, while non-
parametric data sets were assessed by Mann–Whitney test. One-way or two-way
ANOVA followed by Holm–Sidak post hoc method were employed for comparison
of three or more groups which passed normality test. Box-plots show median
(white line) and the 25–75% range as box, the whiskers indicate 5–95% range. No
data points were excluded from the statistical analysis unless otherwise noted.
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Studies using SOD1-G93A mice were all blinded to researcher until data were
grouped. The remaining experiments were not blinded unless otherwise noted.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The source data underlying Fig. 1d, e, g–i, k, l, 2b, d, e, g-j, 3d, e, i–l, 4d, e, h, j, 5b–e, g, h,
j, 6a–i, 7a, b, d–h, l, m, 8, 9f, i and Supplementary Figs. 1, 2, 3c–f, i–k, 4b–d, 5a–c, e–i,
6a–d, f–i, 7, 8b–g, 9a–c, e, g, h, 10–12, 13a–c, e–i, 14 and 15 are provided as a Source Data
file. In situ hybridization images were obtained from © 2004 Allen Institute for Brain
Science. Allen Mouse Brain Atlas. Available from: http://mouse.brain-map.org/ (Fig. 4a)
and from © 2008 Allen Institute for Brain Science. Allen Mouse Spinal Cord Atlas.
Available from: http://mousespinal.brain-map.org/ (Figs. 3a, 9a, b). All other data, raw
images and/or supplemental materials are available from the corresponding author upon
reasonable request.
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